


TOTAL PRODUCTION


Nom de l'équipe : Apoptosis, cancer and immunity

Nom du directeur pour le contrat en cours : Guido KROEMER

Nom du directeur pour le contrat à venir : Guido KROEMER

I. PRODUITS DE LA RECHERCHE

Publications of staff recruited during the last five years and done in their previous team are flagged with 

Publications done in collaboration with another team of the CRC are flagged with 

1. Journaux / revues

Articles scientifiques

2017

1. Moya A, Larochette N, Paquet J, Deschepper M, Bensidhoum M, Izzo V, Kroemer G, Petite H, Logeart-Avramoglou D. Quiescence Preconditioned Human Multipotent Stromal Cells Adopt a Metabolic Profile Favorable for Enhanced Survival Under Ischemia. *Stem Cells*. 2017 Jan;35(1):181-196.
2. Galluzzi L, Kroemer G. Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. *Oncotarget*. 017 Jan 24;8(4):5686-5691
3. Senovilla L, Demont Y, Humeau J, Bloy N, Kroemer G. Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. *Methods Mol Biol*. 2017;1524:53-64.
4. Soussi T, Kroemer G. TP53 and 53BP1 Reunited. *Trends Cell Biol*. 2016 Nov 17. pii: S0962-8924(16)30175-1. doi: 10.1016/j.tcb.2016.10.004. [Epub ahead of print]
5. Galluzzi L, Bravo-San Pedro JM, Demaria S, Formenti SC, Kroemer G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. *Nat Rev Clin Oncol*. 2016 Nov 15. doi: 10.1038/nrclinonc.2016.183. [Epub ahead of print]
6. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. *Nat Rev Immunol*. 2017 Feb;17(2):97-111
7. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Reply: The complement system is also important in immunogenic cell death. *Nat Rev Immunol*. 2017 Feb;17(2):143.
8. Kroemer G, Kepp O, Chan FK, Kroemer G. Necroptosis: mechanisms and relevance to disease. *Annu Rev Pathol*. 2017 Jan 24;12:103-130.
9. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Preface. *Methods Enzymol*. 2017;587:xxiii-xxix.
10. Bravo-San Pedro JM, Pietrocola F, Sica V, Izzo V, Sauvat A, Kepp O, Maiuri MC, Kroemer G, Galluzzi L. High-Throughput Quantification of GFP-LC3+ Dots by Automated Fluorescence Microscopy. *Methods Enzymol*. 2017;587:71-86.

11. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Preface. *Methods Enzymol.* 2017;588:xxv-xxxi.
12. Sauvat A, Zhou H, Leduc M, Gomes-da-Silva LC, Bezu L, Müller K, Forveille S, Liu P, Zhao L, Kroemer G*, Kepp O. (*Corresponding author). Automated Analysis of Fluorescence Colocalization: Application to Mitophagy. *Methods Enzymol.* 2017;588:219-230.
13. Sica V, Bravo-San Pedro JM, Pietrocola F, Izzo V, Maiuri MC, Kroemer G*, Galluzzi L. (*Corresponding author). Assessment of Glycolytic Flux and Mitochondrial Respiration in the Course of Autophagic Responses. *Methods Enzymol.* 2017;588:155-170.
14. Bénit P, Pelhaître A, Saunier E, Bortoli S, Coulibaly A, Rak M, Schiff M, Kroemer G, Zeviani M, Rustin P. Paradoxical Inhibition of Glycolysis by Pioglitazone Opposes the Mitochondriopathy Caused by AIF Deficiency. *EBioMedicine.* 2017 Mar;17:75-87.
15. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Mitophagy: Permitted by Prohibitin. *Curr Biol.* 2017 Jan 23;27(2):R73-R76.
16. Pietrocola F, Kroemer G. Metformin: a metabolic modulator. *Oncotarget.* 2017 Feb 7;8(6):9017-9020.
17. Eisenberg T, Abdellatif M, Zimmermann A, Schroeder S, Pendl T, Harger A, Stekovic S, Schipke J, Magnes C, Schmidt A, Ruckstuhl C, Dambrueck C, Gross AS, Herbst V, Carmona-Gutierrez D, Pietrocola F, Pieber TR, Sigrist SJ, Linke WA, Mühlfeld C, Sadoshima J, Dengjel J, Kiechl S, Kroemer G, Sedej S, Madeo F. Dietary spermidine for lowering high blood pressure. *Autophagy.* 2017 Jan 24:0. doi: 10.1080/15548627.2017.1280225. [Epub ahead of print]
18. López-Soto A, Bravo-San Pedro JM, Kroemer G, Galluzzi L, Gonzalez S. Involvement of autophagy in NK cell development and function. *Autophagy.* 2017 Mar 4;13(3):633-636.
19. Ferrari E, Monzani R, Vilella VR, Esposito S, Saluzzo F, Rossin F, D'Eletto M, Tosco A, De Gregorio F, Maiuri MC, Kroemer G*. Raia V, Maiuri L (*Corresponding author). Cysteamine re-establishes the clearance of *Pseudomonas aeruginosa* by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. *Cell Death Dis.* 2017 Jan 12;8(1):e2544
20. Izzo V, Pietrocola F, Sica V, Zhang S, Durand S, Lachkar S, Enot D, Bravo San Pedro JM, Chery A, Esposito S, Zamzami N, Raia V, Maiuri L, Maiuri MC, Kroemer G. Metabolic interactions between cysteamine and epigallocatechin gallate. *Cell Cycle.* 2017 Feb;16(3):271-279.
21. Pietrocola F, Bravo San Pedro JM, Galluzzi L, Kroemer G. Autophagy in natural and therapy-driven anticancer immunosurveillance. *Autophagy* In press
22. Pietrocola F, Demont Y, F, Enot D, Durand S, Semeraro M, Baracco EE, Pol J, Bravo San-Pedro JM, Bordenave C, Levesque S, Humeau J, Chery A, Metivier D, Madeo F, Maiuri P, Kroemer G. Metabolic effects of starvation on human and mouse leukocytes. *Autophagy.* In press
23. Galluzzi L, Kroemer G. Secondary necrosis. Accidental no more. *Trends Cancer.* In press
24. Sixt B, Bastidas RJ, Finethy R, Baxter RM, Carpenter VK, Kroemer G, Coers J, Valdivia RH. The Chlamydia trachomatis inclusion membrane protein CpoS counteracts cellular surveillance and suicide programs. *Cell Host Microbe.* 2017 Jan 11;21(1):113-121
25. Romani L, Oikomou V, Iannitti RG, D'Adamo MC, Sforza L, Pariano M, Borghi M, Bellet MM, Fallarino F, Pallotta MT, Servillo G, Moretti S, Puccetti P, Ferrari E, Maiuri L, Kroemer G, Pessia M, Goldstein AL, Garaci E. The small molecule thymosin α 1 corrects functional defects and inflammation in cystic fibrosis. *Nat Med.* In press
26. Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles. *Nat Rev Drug Discov.* In press

27. Galluzzi L, Kroemer G. Calreticulin and type I interferon: an unsuspected connection. *OncoImmunology*. In press
28. Zitvogel L, Daillère R, Robert PM, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. *Nat Rev Microbiol*. In press
29. Galluzzi, Bravo-San Pedro JM, Kroemer G. Autophagie, forme et longévité. *Med Sci*. In press
30. Codogno P, Kroemer G. Se manger soi-même, avec modération, une condition pour garder un esprit sain dans un corps sain. *Med Sci*. In press
31. Chlamydia trachomatis' struggle to keep its host alive. Sixt BS, Valdivia RH, Kroemer G. *Microb Cell*. 2017 Mar 2;4(3):101-104.
32. Vitale I, Manic G, Castedo M. Kroemer G. Caspase-2 in mitotic catastrophe: the terminator of aneuploid and tetraploid cells. *Mol Cell Oncol*. In press
33. Stoll G, Ma Y, Yuan H, Kepp O, Zitvogel L, Kroemer G. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. *OncoImmunology*. In press
34. Fend L, Yamazaki T, Prévaille W, Quéménéur E, Kepp O, Adam J, Marabell A, Pitt JM, Kroemer G, Zitvogel L. Immune abscopal effects of an oncolytic virus boosted by immune checkpoint, IFNAR blockade or immunogenic chemotherapy. *Cancer Res*. In press
35. Stoll G, Caron B, Viara E, Dugourd A, Nalid A, Kroemer G. Zinovyev A, Barillot E, Calzone L. MaBoSS 2.0: a tool for stochastic Boolean modeling. *Bioinformatics*, In press
36. Vitale I, Kroemer G. Spontaneous DNA damage propels tumorigenicity. *Cell Res*. 2017 Mar 31. doi: 10.1038/cr.2017.43. [Epub ahead of print]
37. Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L. DNA damage in stem cells. *Mol Cell*. In press
38. Esteban-Martinez L, Salazar-Roa M, Mariño G, Sierra-Filardi E, Seco E, Enot D, Grana O, McGreal RS, Malumbres M, Cvek A, Cuervo AM, Kroemer G, Boya P. Programmed mitophagy is essential for glycolytic switch during cell differentiation. *EMBO J*. In press
39. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AL, Chu CT, Codogno P, Colombo MI, Cuervo AM, Debnath J, Deretic V, Dikic I, Eskelinen EL, Fimia GM, Fulda S, Gewirtz DA, Green DR, Hansen M, Harper W, Jaattela M, Johansen T, Juhasz G, Kimmelman AC, Kraft C, Ktistakis NT, Kumar S, Levine B, Lopez-Otin C, Madeo F, Martens S, Martinez J, Melendez A, Mizushima N, Munz C, Murphy LO, Penninger JM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Santambrogio L, Scorrano L, Simon AK, Simon HU, Somonsen A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Uye Z, Zhong Q, Kroemer G. Molecular definitions of autophagy and related processes. *EMBO J*. In press
40. Zhou X, Xie L, Bergmann F, Endris V, Strobel O, Buchler MW, Kroemer G, Hackert T, Fortunato F. The bile acid receptor FXR represses acinar cell autophagy and promotes chronic pancreatitis. *Cell Death Discov* in press
41. Galluzzi L, Kroemer G. An epigenetic modifier triggers therapeutic immune responses against breast cancer. *OncoImmunology*. In press
42. Bravo San Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in cardiovascular disease. *Circ Res* In press
43. Sun Y, Li T, Xie C, Xu Y, Zhou K, Rodriguez J, Han W, Wang X, Kroemer G, Modjtahedi N, Blomgren K, Zhu C. Haploinsufficiency in the mitochondrial protein CHCHD4 reduces brain in a mouse model of neonatal hypoxia-ischemia. *Cell Death Dis*. In press
44. Sica V, Bravo-San Pedro JM, Marino G, Lachkar S, Izzo V, Maiuri C, Niso-Santano M, Kroemer G. The acetyltransferase Ing4 interacts with Beclin 1 and represses autophagy. *Oncotarget*. In press

45. Fezai M, Slaymi S, Ben-Attia CS, Kroemer G, Lange F, Jemaa M. Inhibition of Colon Carcinoma Cell Migration Following Treatment with Purified Venom from Lesser Weever Fish (*Trachinus Viper*a). *Cell Physiol Biochem*. In press
46. Bonora M, Morganti C, Morciano G, Pediali G, Lebedzinska M, Aquia G, Giorgi C, Rizzo P, Campo G, Ferrari R, Kroemer G, Wieckowski MR, Galluzzi L, Pinton P. Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and correct C-ring conformation. *EMBO Rep*. In Press
47. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Torres C, Chen L, Kwon BS, Anderson AC, Robert C, Borg C, Dalle S, Maio M, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L. Immunophenotyping of stage III melanoma reveals key prognostic factors. *Nat Commun*. In press
48. Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch. Dendritic cell-based anticancer immunotherapy. *Oncol Immunology*. In press
49. Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation & cancer. *Nat Immunol*. In press
50. Fernandez AF, Barcena C, Pietrocola F, Castoldi F, Estaban L, Sierra-Filardi E, Boya P, Lopez-Otin C, Kroemer G*, Mariño G (*Corresponding author). Autophagy counteracts weight gain, lipotoxicity and pancreatic β -cell death upon hypercaloric pro-diabetic regimens. *Cell Death Dis*. In press

2016

51. Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G*, and Zitvogel L (*Corresponding author). Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. *Oncoimmunology*. 2016 May 13;6(1):e1163456.
52. Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic compound LTX-401 targets the Golgi apparatus. *Cell Death Differ*. 2016 Dec;23(12):2031-2041.
53. Esposito S, Tosco A, Vilella VR, Raia V, Kroemer G, Maiuri L. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. *Mol Cell Pediatr*. 2016 Dec;3(1):13.
54. Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, Mathieu MC, Delaloge S, Kroemer G. The ratio of CD8(+)/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. *Oncoimmunology*. 2016 Aug 18;5(10):e1218106.
55. Eisenberg T, Abdellatif M, Schroeder S, Primessnig U, Stekovic S, Pendl T, Harger A, Schipke J, Zimmermann A, Schmidt A, Tong M, Ruckstuhl C, Dammbrueck C, Gross AS, Herbst V, Magnes C, Trausinger G, Narath S, Meinitzer A, Hu Z, Kirsch A, Eller K, Carmona-Gutierrez D, Büttner S, Pietrocola F, Knittelfelder O, Schrepfer E, Rockenfeller P, Simonini C, Rahn A, Horsch M, Moreth K, Beckers J, Fuchs H, Gailus-Durner V, Neff F, Janik D, Rathkolb B, Rozman J, de Angelis MH, Moustafa T, Haemmerle G, Mayr M, Willeit P, von Frieling-Salewsky M, Pieske B, Scorrano L, Pieber T, Pechlaner R, Willeit J, Sigrist SJ, Linke WA, Mühlfeld C, Sadoshima J, Dengiel J, Kiechl S, Kroemer G*, Sedej S, Madeo F. (*Corresponding author). Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat Med*. 2016 Dec;22(12):1428-1438.
56. Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. *Nat Rev Cancer*. 2016 Dec;16(12):759-773.
57. Catani JP, Medrano RF, Hunger A, Del Valle P, Adjemian S, Zanatta DB, Kroemer G, Costanzi-Strauss E, Strauss BE. Intratumoral Immunization by p19Arf and Interferon- β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. *Transl Oncol*. 2016 Dec;9(6):565-574.

58. Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. *Cancer Immunol Res*. 2016 Nov;4(11):895-902.
59. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. *Blood*. 2016 Dec 29;128(26):3113-3124.
60. Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. *Oncoimmunology*. 2016 Jul 25;5(9):e1214790.
61. Fortunato F, Hackert T, Büchler MW, Kroemer G. Retrospective electron microscopy: Preservation of fine structure by freezing and aldehyde fixation. *Mol Cell Oncol*. 2016 Oct 27;3(6):e1251382.
62. Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CP, Flament C, Lepage P, Roberti MP, Routy B, Jacquilot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. *Immunity*. 2016 Oct 18;45(4):931-943.
63. Wiraswati HL, Hangen E, Sanz AB, Lam NV, Reinhardt C, Sauvat A, Mogha A, Ortiz A, Kroemer G, Modjtahedi N. Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione. *Oncotarget*. 2016 Nov 22;7(47):76496-76507.
64. Tortola L, Nitsch R, Bertrand MJ, Kogler M, Redouane Y, Kozieradzki I, Uribealago I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, Hanada T, Takahashi N, Kernbauer E, Demiröz D, Lang M, Superti-Furga G, Decker T, Pichler A, Ikeda F, Kroemer G, Vandenabeele P, Sorensen PH, Penninger JM. The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. *Cell Rep*. 2016 Sep 20;16(12):3414.
65. Galluzzi L, Kroemer G. Aberrant ketolysis fuels hepatocellular cancer progression. *Cell Res*. 2016 Oct;26(10):1077-1078.
66. Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G. Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. *Oncoimmunology*. 2016 Jun 9;5(7):e1177692.
67. Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic compound LTX-401 targets the Golgi apparatus. *Cell Death Differ*. 2016 Dec;23(12):2031-2041.
68. Pietrocola F, Pol J, Kroemer G. Fasting improves anticancer immunosurveillance via autophagy induction in malignant cells. *Cell Cycle*. 2016 Dec 16;15(24):3327-3328.
69. Missiroli S, Bonora M, Patergnani S, Poletti F, Perrone M, Gafà R, Magri E, Raimondi A, Lanza G, Tacchetti C, Kroemer G, Pandolfi PP, Pinton P, Giorgi C. PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development. *Cell Rep*. 2016 Aug 30;16(9):2415-27.
70. Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Chiara Maiuri M, Madeo F, Kroemer G. Autophagy induction for the treatment of cancer. *Autophagy*. 2016 Oct 2;12(10):1962-1964.
71. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic Control of Longevity. *Cell*. 2016 Aug 11;166(4):802-21.
72. Pitt JM, Vétizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, Zitvogel L. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. *Cancer Res*. 2016 Aug 15;76(16):4602-7.

73. Ladoire S, Enot D, Senovilla L, Chaix M, Zitvogel L, Kroemer G. Positive impact of autophagy in human breast cancer cells on local immunosurveillance. *Oncoimmunology*. 2016 May 24;5(6):e1174801.
74. Ladoire S, Senovilla L, Enot D, Ghiringhelli F, Poirier-Colame V, Chaba K, Erdag G, Schaefer JT, Deacon DH, Zitvogel L, Slingluff CL Jr, Kroemer G. Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. *Oncoimmunology*. 2016 Mar 16;5(6):e1160193.
75. Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. *Oncoimmunology*. 2016 Mar 10;5(6):e1149674.
76. Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. *Oncoimmunology*. 2016 Mar 10;5(6):e1149673.
77. Baracco EE, Pietrocola F, Buqué A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. *Oncoimmunology*. 2016 Feb 18;5(6):e1139275.
78. Kroemer G, Galluzzi L, Zitvogel L. STAT3 inhibition for cancer therapy: Cell-autonomous effects only? *Oncoimmunology*. 2016 Jan 8;5(5):e1126063.
79. Vacchelli E, Ma Y, Baracco EE, Zitvogel L, Kroemer G. Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. *Oncoimmunology*. 2016 Mar 30;5(5):e1118600.
80. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquilot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G. Caloric restriction mimetics enhance anticancer immunosurveillance. *Cancer Cell*. 2016 Jul 11;30(1):147-60.
81. Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. *Immunity*. 2016 Jun 21;44(6):1255-69.
82. Zitvogel L, Kroemer G. Unchaining NK cell-mediated anticancer immunosurveillance. *Nat Immunol*. 2016 Jun 21;17(7):746-7.
83. Galluzzi L, Buqué A, Kroemer G. Prevention of breast cancer by RANKL/RANK blockade. *Cell Res*. 2016 Jul;26(7):751-2.
84. Lichtmanegger J, Leitzinger C, Wimmer R, Schmitt S, Schulz S, Kabiri Y, Eberhagen C, Rieder T, Janik D, Neff F, Straub BK, Schirmacher P, DiSpirito AA, Bandow N, Baral BS, Flatley A, Kremmer E, Denk G, Reiter FP, Hohenester S, Eckardt-Schupp F, Dencher NA, Adamski J, Sauer V, Niemietz C, Schmidt HH, Merle U, Gotthardt DN, Kroemer G, Weiss KH, Zischka H. Methanobactin reverses acute liver failure in a rat model of Wilson disease. *J Clin Invest*. 2016 Jul 1;126(7):2721-35.
85. Modjtahedi N, Kroemer G. CHCHD4 links AIF to the biogenesis of respiratory chain complex I. *Mol Cell Oncol*. 2015 Jul 29;3(2):e1074332.
86. Rockenfeller P, Carmona-Gutierrez D, Pietrocola F, Kroemer G, Madeo F. Ethanolamine: A novel anti-aging agent. *Mol Cell Oncol*. 2015 Mar 19;3(1):e1019023.
87. Galluzzi L, Bravo-San Pedro JM, Blomgren K, Kroemer G. Autophagy in acute brain injury. *Nat Rev Neurosci*. 2016 Aug;17(8):467-84
88. Sica V, Manic G, Kroemer G, Vitale I, Galluzzi L. Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. *Methods Mol Biol*. 2016;1417:231-45.

89. Galluzzi L, Kroemer G. A four-lane highway to cancer. *Nat Rev Mol Cell Biol.* 2016 Jul;17(7):398.
90. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Defective Autophagy Initiates Malignant Transformation. *Mol Cell.* 2016 May 19;62(4):473-4.
91. Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. *Cancer Res.* 2016 Jun 1;76(11):3122-6.
92. Mondragón L, Kroemer G, Galluzzi L. Immunosuppressive $\gamma \delta$ T cells foster pancreatic carcinogenesis. *Oncoimmunology.* 2016 Sep 27;5(11):e1237328.
93. Izzo V, Bravo-San Pedro JM, Sica V, Kroemer G, Galluzzi L. Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties. *Trends Cell Biol.* 2016 Sep;26(9):655-67.
94. Tortola L, Nitsch R, Bertrand MJ, Kogler M, Redouane Y, Kozieradzki I, Uribealago I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, Hanada T, Takahashi N, Kernbauer E, Demiröz D, Superti-Furga G, Decker T, Pichler A, Ikeda F, Kroemer G, Vandenabeele P, Sorensen PH, Penninger JM. The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. *Cell Rep.* 2016 May 17;15(7):1481-92.
95. Kroemer G. Dying cell recognition shapes the pathophysiology of cell death. *Cell Death Differ.* 2016 Jun;23(6):913-4.
96. Sica V, Maiuri MC, Kroemer G, Galluzzi L. Detection of Apoptotic Versus Autophagic Cell Death by Flow Cytometry. *Methods Mol Biol.* 2016;1419:1-16.
97. Galluzzi L, Kroemer G. Amino acid deprivation promotes intestinal homeostasis through autophagy. *Oncotarget.* 2016 May 24;7(21):29877-8.
98. Yamazaki T, Pitt JM, Vétizou M, Marabelle A, Flores C, Rekdal Ø, Kroemer G*, Zitvogel L. (*Corresponding author). The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. *Cell Death Differ.* 2016 Jun;23(6):1004-15.
99. Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. *Ann Oncol.* 2016 Apr 10. pii: mdw168. [Epub ahead of print]
100. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. *Cell.* 2016 Apr 7;165(2):276-87.
101. Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G*, Galluzzi L (*Corresponding author). Trial Watch-Oncolytic viruses and cancer therapy. *Oncoimmunology.* 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb.
102. Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch-Immunostimulation with cytokines in cancer therapy. *Oncoimmunology.* 2015 Dec 8;5(2):e1115942. eCollection 2016 Feb.
103. Ladoire S, Enot D, Andre F, Zitvogel L, Kroemer G. Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. *Oncoimmunology.* 2015 Aug 31;5(2):e1082706. eCollection 2016 Feb.
104. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. Improvement of immunogenic chemotherapy by STAT3 inhibition. *Oncoimmunology.* 2015 Sep 11;5(2):e1078061. eCollection 2016 Feb.
105. Stoll G, Zitvogel L, Kroemer G. Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. *Oncoimmunology.* 2015 Sep 11;5(2):e1067746. eCollection 2016 Feb.

106. Vacchelli E, Semeraro M, Adam J, Dartigues P, Zitvogel L, Kroemer G. Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. *Oncoimmunology*. 2015 Jul 1;5(2):e1064581. eCollection 2016 Feb.
107. Galluzzi L, Bravo-San Pedro JM, Kepp O, Kroemer G. Regulated cell death and adaptive stress responses. *Cell Mol Life Sci*. 2016 Jun;73(11-12):2405-10.
108. Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. *J Clin Invest*. 2016 Apr 1;126(4):1224-32.
109. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. *J Clin Invest*. 2016 Apr 1;126(4):1139-43.
110. Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA, Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G*, Maiuri L, Raia V. (*Corresponding author). A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. *Cell Death Differ*. 2016 Aug;23(8):1380-93.
111. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. *Nat Rev Clin Oncol*. 2016 Jul;13(7):431-46.
112. Kohrt HE, Tumei PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immunoncology clinical trials. *J Immunother Cancer*. 2016 Mar 15;4:15.
113. Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, Poillot ML, Arveux P, Delaloge S, André F, Zitvogel L, Kroemer G. The Presence Of Lc3b Puncta And Hmgb1 Expression In Malignant Cells Correlate With The Immune Infiltrate In Breast Cancer. *Autophagy*. 2016 May 3;12(5):864-75.
114. Esposito S, Tosco A, Vilella VR, Raia V, Kroemer G, Maiuri L. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. *Mol Cell Pediatr*. 2016 Dec;3(1):13. doi: 10.1186/s40348-016-0040-z.
115. Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, Liu P, Yang H, Bezu L, Müller K, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 triggers immunogenic cell death. *Cell Death Dis*. 2016 Mar 10;7:e2134.
116. Ma Y, Yang H, Pitt JM, Kroemer G, Zitvogel L. Therapy-induced microenvironmental changes in cancer. *J Mol Med (Berl)*. 2016 May;94(5):497-508
117. Mollereau B, Rzechorzek NM, Roussel BD, Sedru M, Van den Brink D, Bailly-Maitre B, Palladino F, Medinas DB, Domingos PM, Hunot S, Chandran S, Birman S, Baron T, Vivien D, Duarte CB, Ryoo HD, Steller H, Urano F, Chevet E, Kroemer G, Ciechanover A, Calabrese EJ, Kaufman RJ, Hetz C. Adaptive Preconditioning in Neurological Diseases - Therapeutic Insights from Proteostatic Perturbations. *Brain Res*. 2016 Feb 25. In press
118. Galluzzi L, López-Soto A, Kumar S, Kroemer G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. *Immunity*. 2016 Feb 16;44(2):221-231.
119. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, Lin YJ, Wojtkiewicz G, Iwamoto Y, Mino-Kenudson M, Huynh TG, Hynes RO, Freeman GJ, Kroemer G, Zitvogel L, Weissleder R, Pittet MJ. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. *Immunity*. 2016 Feb 16;44(2):343-354.

120. Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. *J Clin Invest*. 2016 Mar 1;126(3):921-37.
121. Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautes-Fridman C, Cremer I. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. *Cancer Res*. 2016 Apr 1;76(7):1746-56.
122. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C, Weide B, Aubin F, Dalle S, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L. Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis. *J Invest Dermatol*. 2016 May;136(5):994-1001.
123. Klionsky D, ... Kroemer G... Zughraier SM. Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy. 3rd Edition. *Autophagy*. 2016 Jan 2;12(1):1-222.
124. Modjtahedi N, Tokatlidis K, Dessen P, Kroemer G. Mitochondrial Proteins Containing Coiled-Coil-Helix-Coiled-Coil-Helix (CHCH) Domains in Health and Disease. *Trends Biochem Sci*. 2016 Mar;41(3):245-60.
125. Galluzzi L, Kepp O, Kroemer G. Mitochondrial regulation of cell death: a phylogenetically conserved control. *Microb Cell*. 2016 Feb 23;3(3):101-108.
126. Jemaà M, Manic G, Lledo G, Lissa D, Reynes C, Morin N, Chibon F, Sistigu A, Castedo M, Vitale I, Kroemer G*, Abrieu A. (*Corresponding author). Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. *Oncotarget*. 2016 Jan 5;7(1):885-901.
127. Xie C, Ginet V, Sun Y, Koike M, Zhou K, Li T, Li H, Li Q, Wang X, Uchiyama Y, Truttmann AC, Kroemer G, Puyal J, Blomgren K, Zhu C. Neuroprotection by selective neuronal deletion of Atg7 in neonatal brain injury. *Autophagy*. 2016 Feb;12(2):410-23.
128. Hermanova I, Arruabarrena-Aristorena A, Valis K, Nuskova H, Alberich-Jorda M, Fiser K, Fernandez-Ruiz S, Kavan D, Pecinova A, Niso-Santano M, Zaliova M, Novak P, Houstek J, Mracek T, Kroemer G, Carracedo A, Trka J, Starkova J. Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. *Leukemia*. 2016 Jan;30(1):209-18.
129. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Autophagy Mediates Tumor Suppression via Cellular Senescence. *Trends Cell Biol*. 2016 Jan;26(1):1-3.

2015

130. Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špišek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. *Oncoimmunology*. 2015 Sep 2;5(3):e1088631.
131. Marabelle A, Routy B, Michels J, Kroemer G, Zitvogel L. Prime time for immune-checkpoint targeted therapy at ASCO 2015. *Oncoimmunology*. 2015 Aug 12;5(3):e1068494.
132. Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. *Oncoimmunology*. 2015 Dec 8;5(1):e1115641.
133. Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. *Oncoimmunology*. 2015 Oct 29;5(1):e1106127.
134. Senovilla L, Kroemer G. Chemosensitization strategies for the treatment of lung cancer. *Oncoscience*. 2015 Aug 20;2(10):833-4

135. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. *Cancer Cell*. 2015 Dec 14;28(6):690-714.
136. Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruyscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaip US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroeder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. *Front Immunol*. 2015 Nov 20;6:588.
137. Galluzzi L, Kroemer G. Defective autophagy gets to the brain. *Oncotarget*. 2015 Nov 24;6(37):39396-7.
138. Forveille S, Zhou H, Sauvat A, Bezu L, Müller K, Liu P, Zitvogel L, Pierron G, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 triggers necrotic cell death. *Cell Cycle*. 2015 Nov 2;14(21):3506-12.
139. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharaf S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquilot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015 Nov 27;350(6264):1079-84.
140. Galluzzi L, Pietrocola F, Kroemer G. Molecular Regulation of Circadian Rhythms by Polyamines. *Cell Metab*. 2015 Nov 3;22(5):757-8.
141. Bloy N, Sauvat A, Chaba K, Buqué A, Humeau J, Bravo-San Pedro JM, Bui J, Kepp O, Kroemer G, Senovilla L. Morphometric analysis of immunoselection against hyperploid cancer cells. *Oncotarget*. 2015 Oct 15. doi: 10.18632/oncotarget.5400. [Epub ahead of print]
142. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delalogue S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science*. 2015 Nov 20;350(6263):972-8.
143. Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delalogue S, Poillot ML, Arveux P, Goubar A, André F, Zitvogel L, Kroemer G. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. *Autophagy*. 2015 Oct 3;11(10):1878-90.
144. Seah S, Low IC, Hirpara JL, Sachaphibulkij K, Kroemer G, Brenner C, Pervaiz S. Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells. *Cell Death Dis*. 2015 Oct 22;6:e1926. PMID: PMC4632318.
145. Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for oncological indications. *Oncoimmunology*. 2015 May 5;4(11):e1046673.
146. Semeraro M, Rusakiewicz S, Zitvogel L, Kroemer G. Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. *Oncoimmunology*. 2015 May 5;4(11):e1042202.
147. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. *Nat Med*. 2015 Oct 7;21(10):1128-38.
148. Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G. Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. *Oncoimmunology*. 2015 Jul 25;4(8):e988042.

149. Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olausson KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G. Negative prognostic value of high levels of intracellular poly (ADP-ribose) in non-small cell lung cancer. *Ann Oncol*. 2015 Dec;26(12):2470-7.
150. Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S, Müller K, Liu P, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. *Oncotarget*. 2015 Sep 29;6(29):26599-614.
151. Piacentini M, Kroemer G. Dying to survive - apoptosis, necroptosis, autophagy as supreme experiments of nature. *Int J Dev Biol*. 2015;59(1-3):5-9.
152. Vacchelli E, Semeraro M, Enot DP, Chaba K, Poirier Colame V, Dartigues P, Perier A, Villa I, Rusakiewicz S, Gronnier C, Goéré D, Mariette C, Zitvogel L, Kroemer G. Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. *Oncotarget*. 2015 Aug 28;6(25):20840-50.
153. Zitvogel L, Kroemer G. Subversion of anticancer immunosurveillance by radiotherapy. *Nat Immunol*. 2015 Sep 18;16(10):1005-7.
154. Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. *Front Immunol*. 2015 Aug 7;6:402.
155. Sica V, Galluzzi L, Bravo-San Pedro JM, Izzo V, Maiuri MC, Kroemer G. Organelle-Specific Initiation of Autophagy. *Mol Cell*. 2015 Aug 20;59(4):522-39.
156. Gentili M, Kowal J, Tkach M, Satoh T, Lahaye X, Conrad C, Boyron M, Lombard B, Durand S, Kroemer G, Loew D, Dalod M, Théry C, Manel N. Transmission of innate immune signaling by packaging of cGAMP in viral particles. *Science*. 2015 Jul 31;349(6247):476-7
157. Zitvogel L, Kroemer G. A p53-regulated immune checkpoint relevant to cancer. *Science*. 2015 Jul 31;349(6247):476-477.
158. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. *Cancer Res*. 2015 Sep 15;75(18):3812-22
159. Modjtahedi N, Hangen E, Gonin P, Kroemer G. Metabolic epistasis among apoptosis-inducing factor and the mitochondrial import factor CHCHD4. *Cell Cycle*. 2015;14(17):2743-7.
160. Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. *Oncoimmunology*. 2015 Mar 2;4(6):e1008853.
161. Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. *Oncoimmunology*. 2015 Apr 2;4(5):e1026531.
162. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Ferroptosis in p53-dependent oncosuppression and organismal homeostasis. *Cell Death Differ*. 2015 Aug;22(8):1237-8.
163. Stoll G, Zitvogel L, Kroemer G. Immune infiltrate in cancer. *Aging* (Albany NY). 2015 Jun;7(6):358-9.
164. Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? *Oncoimmunology*. 2015 Jun 5;4(7):e1058597.
165. Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. *Oncoimmunology*. 2015 Jun 3;4(7):e1058037.

166. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide-based anticancer vaccines. *Oncoimmunology*. 2015 Jan 9;4(4):e974411.
167. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. *Oncoimmunology*. 2015 Mar 2;4(4):e1008866.
168. Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *Oncoimmunology*. 2015 Mar 2;4(4):e1008814.
169. Enot DP, Niso-Santano M, Durand S, Chery A, Pietrocola F, Vacchelli E, Madeo F, Galluzzi L, Kroemer G. Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. *Cell Cycle*. 2015 Aug 3;14(15):2399-407.
170. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Necrosis: Linking the Inflammasome to Inflammation. *Cell Rep*. 2015 Jun 16;11(10):1501-2.
171. Bezu L, Gomes-da-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Combinatorial Strategies for the Induction of Immunogenic Cell Death. *Front Immunol*. 2015 Jun 1;6:275.
172. Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. *Oncotarget*. 2015 May 20;6(14):11894-909.
173. Maiuri L, De Stefano D, Raia V, Kroemer G. The holy grail of cystic fibrosis research: pharmacological repair of the F508del-CFTR mutation. *Ann Transl Med*. 2015 May;3(Suppl 1):S24.
174. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl Coenzyme A: A Central Metabolite and Second Messenger. *Cell Metab*. 2015 Jun 2;21(6):805-821.
175. Bouvier M, Chneiweiss H, Jordan B, Lagrue G, Ménard J, Teillaud JL, Kroemer G, Moulin AM, Flahault A, Lafanechère L, Maréchal É, Guillemot JC, Gaille M. Les années 2010. *Med Sci (Paris)*. 2015 Mar;31 Spec No 1:91-111.
176. Peschanski M, Bergeron M, Boué A, Coppens Y, Changeux JP, Corvol P, Lazar P, Kahn A, Bichet DG, Friedlander G, Epelbaum J, Kroemer G, Chneiweiss H, Munnich A, Bouvier M, Jordan B, Frydman R, Morange M, Fougereau M. Les années 2000. *Med Sci (Paris)*. 2015 Mar;31 Spec No 1:47-90.
177. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. *Nat Rev Immunol*. 2015 Jul;15(7):405-14.
178. Hangen E, Féraud O, Lachkar S, Mou H, Doti N, Fimia GM, Lam NV, Zhu C, Godin I, Muller K, Chatzi A, Nuebel E, Ciccocanti F, Flamant S, Bénit P, Perfettini JL, Sauvat A, Bennaceur-Griscelli A, Ser-Le Roux K, Gonin P, Tokatlidis K, Rustin P, Piacentini M, Ruvo M, Blomgren K, Kroemer G*, Modjtahedi N. (*Corresponding and co-senior author). Interaction between AIF and CHCHD4 Regulates Respiratory Chain Biogenesis. *Mol Cell*. 2015 Jun 18;58(6):1001-14.
179. Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. *Oncoimmunology*. 2015 Feb 3;4(1):e985940.
180. Zitvogel L, Kroemer G. Cancer: Antibodies regulate antitumour immunity. *Nature*. 2015 May 7;521(7550):35-7.

181. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G*, Valteau-Couanet D, Zitvogel L. (*Corresponding author). Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. *Sci Transl Med*. 2015 Apr 15;7(283):283ra55.
182. Sauvat A, Wang Y, Segura F, Spaggiari S, Müller K, Zhou H, Galluzzi L, Kepp O, Kroemer G. Quantification of cellular viability by automated microscopy and flow cytometry. *Oncotarget*. 2015 Apr 20;6(11):9467-75
183. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, Pinton P. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. *Oncogene*. 2015 Mar 19;34(12): 1475-1486.
184. Kroemer G, Bravo-San Pedro JM, Galluzzi L. Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum. *Cell Death Dis*. 2015 Mar 19;6:e1698.
185. Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, van Leeuwen FW, Kroemer G, Madeo F. Accumulation of Basic Amino Acids at Mitochondria Dictates the Cytotoxicity of Aberrant Ubiquitin. *Cell Rep*. 2015 Mar 3. pii: S2211-1247(15)00137-0.
186. Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buqué A, Huang X, Zhou H, Senovilla L, Kroemer G, Galluzzi L. eIF2 α phosphorylation as a biomarker of immunogenic cell death. *Semin Cancer Biol*. 2015 Aug;33:86-92.
187. Pedro JM, Wei Y, Sica V, Maiuri MC, Zou Z, Kroemer G*, Levine B. (*Corresponding author). BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. *Autophagy*. 2015 Mar 4;11(3):452-9.
188. Niso-Santano M, Bravo-San Pedro JM, Maiuri MC, Tavernarakis N, Cecconi F, Madeo F, Codogno P, Galluzzi L, Kroemer G. Novel inducers of BECN1-independent autophagy: cis-unsaturated fatty acids. *Autophagy*. 2015 Mar 4;11(3):575-7.
189. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G. Autophagy in malignant transformation and cancer progression. *EMBO J*. 2015 Apr 1;34(7):856-80.
190. Maiuri MC, Kroemer G. Autophagy in stress and disease. *Cell Death Differ*. 2015 Mar;22(3):365-6.
191. Madeo F, Zimmermann A, Maiuri MC, Kroemer G. Essential role for autophagy in life span extension. *J Clin Invest*. 2015 Jan;125(1):85-93.
192. Kroemer G. Autophagy: a druggable process that is deregulated in aging and human disease. *J Clin Invest*. 2015 Jan;125(1):1-4.
193. Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. *Sci Transl Med*. 2015 Jan 21;7(271):271ps1.
194. Niso-Santano M, Malik SA, Pietrocola F, Bravo-San Pedro JM, Mariño G, Cianfanelli V, Ben-Younès A, Troncoso R, Markaki M, Sica V, Izzo V, Chaba K, Bauvy C, Dupont N, Kepp O, Rockenfeller P, Wolinski H, Madeo F, Lavandro S, Codogno P, Harper F, Pierron G, Tavernarakis N, Cecconi F, Maiuri MC, Galluzzi L, Kroemer G. Unsaturated fatty acids induce non-canonical autophagy. *EMBO J*. 2015 Apr 15;34(8):1025-41.

195. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G*, Zitvogel L. (*Corresponding author). Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. *Cell Res*. 2015 Feb;25(2):208-24.
196. Musahl AS, Huang X, Rusakiewicz S, Ntini E, Marsico A, Kroemer G, Kepp O, Ørom UA. A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription. *Oncogene*. 2015 Jan 12. doi: 10.1038/onc.2014.424. [Epub ahead of print] PubMed PMID: 25579178.
197. Rockenfeller P, Koska M, Pietrocola F, Minois N, Knittelfelder O, Sica V, Franz J, Carmona-Gutierrez D, Kroemer G*, Madeo F. (*Corresponding author). Phosphatidylethanolamine positively regulates autophagy and longevity. *Cell Death Differ*. 2015 Mar;22(3):499-508.
198. Maiuri MC, Kroemer G. Essential role for oxidative phosphorylation in cancer progression. *Cell Metab*. 2015 Jan 6;21(1):11-2.
199. Pietrocola F, Lachkar S, Enot DP, Niso-Santano M, Bravo-San Pedro JM, Sica V, Izzo V, Maiuri MC, Madeo F, Mariño G, Kroemer G. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. *Cell Death Differ*. 2015 Mar;22(3):509-16.
200. Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, Leeuwen FW, Kroemer G, Madeo F. Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. *Microb Cell*. 2015 Mar 20;2(4):136-138.
201. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ*. 2015 Jan;22(1):58-73.
202. Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, Kepp O, Khadra N, Enot D, Pfirschke C, Pittet M, Zitvogel L, Kroemer G*, Senovilla L. (*Corresponding author) Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. *Oncogene*. 2015 Jun 4;34(23):3053-62.
203. Vitale I, Manic G, Senovilla L, Kroemer G*, Galluzzi L. (*Corresponding author). Karyotypic aberrations in oncogenesis and cancer therapy. *Trends Cancer* 2015 Oct;1(2):124-135

2014

204. Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial watch: IDO inhibitors in cancer therapy. *Oncoimmunology*. 2014 Dec 15;3(10):e957994.

205. Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial watch: Dendritic cell-based anticancer therapy. *Oncoimmunology*. 2014 Dec 21;3(11):e963424.
206. Galluzzi L, Kroemer G*, Eggermont A. (*Corresponding author). Novel immune checkpoint blocker approved for the treatment of advanced melanoma. *Oncoimmunology*. 2014 Dec 21;3(11):e967147.
207. Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch: Radioimmunotherapy for oncological indications. *Oncoimmunology*. 2014 Dec 13;3(9):e954929.
208. Aranda F, Bloy N, Galluzzi L, Kroemer G*, Senovilla L. (*Corresponding author). Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. *Oncoimmunology*. 2014 Dec 13;3(9):e955685.
209. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipf US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Consensus guidelines for the detection of immunogenic cell death. *Oncoimmunology*. 2014 Dec 13;3(9):e955691.
210. Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. *Mol Cell Oncol*. 2014 Dec 1;2(2):e974463.
211. Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. *Mol Cell Oncol*. 2014 Oct 31;1(2):e977612.
212. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. *Mol Cell Oncol*. 2014 Jul 15;1(1):e29911.
213. Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. *Mol Cell Oncol*. 2014 May 1;1(1):e29052.
214. Galluzzi L, Vacchelli E, Bravo-San Pedro J, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado J, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay J, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach J, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. *Oncotarget*. 2014 Dec 30;5(24):12472-508.
215. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic Control of Autophagy. *Cell*. 2014 Dec 4;159(6):1263-1276.
216. Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; On behalf of the Groupe Francophone des Myelodysplasies (GFM). A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. *Leuk Res*. 2014 Oct 7;38(12):1430-1434.

217. Stefano DD, Vilella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, Maiuri MC, Pettoello-Mantovani M, Guido S, Bossi A, Zolin A, Venerando A, Pinna LA, Mehta A, Bona G, Kroemer G*, Maiuri L, Raia V (*Corresponding author). Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. *Autophagy*. 2014 Nov 2;10(11):2053-74
218. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Prévaille X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G*, Zitvogel L. (*Corresponding author). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *Nat Med*. 2014 Nov;20(11):1301-9.
219. Kroemer G, Perfettini JL. Entosis, a key player in cancer cell competition. *Cell Res*. 2014 Nov;24(11):1280-1.
220. Zitvogel L, Kroemer G. Cytokines reinstate NK cell-mediated cancer immunosurveillance. *J Clin Invest*. 2014 Nov 3;124(11):4687-9.
221. Zitvogel L, Kroemer G. CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. *Cancer Cell*. 2014 Nov 10;26(5):591-3.
222. Zitvogel L, Kroemer G. Targeting foxp1 for reinstating anticancer immunosurveillance. *Immunity*. 2014 Sep 18;41(3):345-7.
223. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. *Science*. 2014 Sep 19;345(6203):1250256.
224. Lorient Y, Mordant P, Dugue D, Geneste O, Gombos A, Opolon P, Guegan J, Perfettini JL, Pierre A, Berthier LK, Kroemer G, Soria JC, Depil S, Deutsch E. Radiosensitization by a novel Bcl-2 and Bcl-X(L) inhibitor S44563 in small-cell lung cancer. *Cell Death Dis*. 2014 Sep 18;5:e1423.
225. Madeo F, Pietrocola F, Eisenberg T, Kroemer G. Caloric restriction mimetics: towards a molecular definition. *Nat Rev Drug Discov*. 2014 Oct;13(10):727-40.
226. Michels J, Obrist F, Castedo M, Vitale I, Kroemer G. PARP and other prospective targets for poisoning cancer cell metabolism. *Biochem Pharmacol*. 2014 Nov 1;92(1):164-71.
227. Kroemer G. Regulated necrosis. *Semin Cell Dev Biol*. Semin Cell Dev Biol. 2014 Nov;35:1.
228. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anticancer agents. *Oncotarget*. 2014 Jul 30;5(14):5190-1.
229. Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G. MCL-1 dependency of cisplatin-resistant cancer cells. *Biochem Pharmacol*. 2014 Nov 1;92(1):55-61.
230. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Prévaille X, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch:: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 2014 Jun 1;3:e28694.
231. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial watch: Immunostimulatory cytokines in cancer therapy. *Oncoimmunology*. 2014 Jun 3;3:e29030.
232. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. *Nat Cell Biol*. 2014 Aug;16(8):728-36.

233. Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, Kroemer G. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. *Oncoimmunology*. 2014 Apr 16;3:e28473.
234. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G*, Galluzzi L (*Corresponding author). Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *Oncoimmunology*. 2014 May 1;3:e28344.
235. Michaud M, Sukkurwala AQ, Di Sano F, Zitvogel L, Kepp O, Kroemer G. Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. *Oncoimmunology*. 2014 Mar 25;3:e28276.
236. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. *Curr Opin Immunol*. 2014 Jun 17;30C:24-31. doi: 10.1016/j.coi.2014.05.009. [Epub ahead of print]
237. Galluzzi L, Kroemer G. Preface: oncometabolism: a new field of research with profound therapeutic implications. *Methods Enzymol*. 2014;542:xix-xxiii and 2014;543:xv-xix.
238. Scoazec M, Durand S, Chery A, Galluzzi L, Kroemer G. Metabolomic profiling of cultured cancer cells. *Methods Enzymol*. 2014;543:165-78.
239. Nassif M, Valenzuela V, Rojas-Rivera D, Vidal R, Matus S, Castillo K, Fuentealba Y, Kroemer G, Levine B, Hetz C. Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. *Autophagy*. 2014 Jul;10(7):1256-71.
240. Schroeder S, Pendl T, Zimmermann A, Eisenberg T, Carmona-Gutierrez D, Ruckenstuhl C, Mariño G, Pietrocola F, Harger A, Magnes C, Sinner F, Pieber TR, Dengjel J, Sigrist SJ, Kroemer G*, Madeo F (*Corresponding author). Acetyl-coenzyme A: a metabolic master regulator of autophagy and longevity. *Autophagy*. 2014 Jul;10(7):1335-7.
241. Troncoso R, Paredes F, Parra V, Gatica D, Vásquez-Trincado C, Quiroga C, Bravo-Sagua R, López-Crisosto C, Rodríguez AE, Oyarzún AP, Kroemer G, Lavandero S. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. *Cell Cycle*. 2014 Jul 15;13(14):2281-95.
242. Eisenberg T, Schroeder S, Büttner S, Carmona-Gutierrez D, Pendl T, Andryushkova A, Mariño G, Pietrocola F, Harger A, Zimmermann A, Magnes C, Sinner F, Sedej S, Pieber TR, Dengjel J, Sigrist S, Kroemer G*, Madeo F (*Corresponding author). A histone point mutation that switches on autophagy. *Autophagy*. 2014 Jun;10(6):1143-5.
243. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. *Cell Death Dis*. 2014 May 29;5:e1257.
244. Teillaud JL, Kroemer G. [Cancer cells and their environments: friends and foes]. *Med Sci (Paris)*. 2014 Apr;30(4):343-4.
245. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. *Oncoimmunology*. 2014 Jan 1;3(1):e28185.
246. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology*. 2014 Jan 1;3(1):e27878.
247. Ma Y, Adjemian S, Galluzzi L, Zitvogel L, Kroemer G. Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. *Oncoimmunology*. 2014 Jan 1;3(1):e27663. E
248. Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. *Oncoimmunology*. 2014 Jan 1;3(1):e27884.

249. Ruckenstuhl C, Netzberger C, Entfellner I, Carmona-Gutierrez D, Kickenweiz T, Stekovic S, Gleixner C, Schmid C, Klug L, Sorgo AG, Eisenberg T, Büttner S, Mariño G, Koziel R, Jansen-Dürr P, Fröhlich KU, Kroemer G, Madeo F. Lifespan extension by methionine restriction requires autophagy-dependent vacuolar acidification. *PLoS Genet.* 2014 May 1;10(5):e1004347.
250. Pietrocola F, Malik SA, Mariño G, Vacchelli E, Senovilla L, Chaba K, Niso-Santano M, Maiuri MC, Madeo F, Kroemer G. Coffee induces autophagy in vivo. *Cell Cycle.* 2014 Jun 15;13(12):1987-94.
251. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, Pinton P. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. *Oncogene.* 2014 Apr 14;0. doi: 10.1038/onc.2014.96. [Epub ahead of print]
252. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *Oncoimmunology.* 2014 Jan 1;3(1):e27297.
253. Mariño G, Pietrocola F, Kong Y, Eisenberg T, Hill JA, Madeo F, Kroemer G. Dimethyl α -ketoglutarate inhibits maladaptive autophagy in pressure overload-induced cardiomyopathy. *Autophagy.* 2014 May;10(5):930-2.
254. Eisenberg T, Schroeder S, Andryushkova A, Pendl T, Küttner V, Bhukel A, Mariño G, Pietrocola F, Harger A, Zimmermann A, Moustafa T, Sprenger A, Jany E, Büttner S, Carmona-Gutierrez D, Ruckenstuhl C, Ring J, Reichelt W, Schimmel K, Leeb T, Moser C, Schatz S, Kamolz LP, Magnes C, Sinner F, Sedej S, Fröhlich KU, Juhasz G, Pieber TR, Dengjel J, Sigrist SJ, Kroemer G*, Madeo F (*Corresponding author). Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates autophagy and prolongs lifespan. *Cell Metab.* 2014 Mar 4;19(3):431-44.
255. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. *Oncoimmunology.* 2014 Jan 1;3(1):e27048.
256. Galluzzi L, Kepp O, Krautwald S, Kroemer G, Linkermann A. Molecular mechanisms of regulated necrosis. *Semin Cell Dev Biol.* 2014 Feb 26. pii: S1084-9521(14)00018-4. doi: 10.1016/j.semdb.2014.02.006. [Epub ahead of print]
257. Mariño G, Pietrocola F, Eisenberg T, Kong Y, Malik SA, Andryushkova A, Schroeder S, Pendl T, Harger A, Niso-Santano M, Zamzami N, Scoazec M, Durand S, Enot DP, Fernández AF, Martins I, Kepp O, Senovilla L, Bauvy C, Morselli E, Vacchelli E, Bennetzen M, Magnes C, Sinner F, Pieber T, López-Otín C, Maiuri MC, Codogno P, Andersen JS, Hill JA, Madeo F, Kroemer G. Regulation of autophagy by cytosolic acetyl-coenzyme A. *Mol Cell.* 2014 Mar 6;53(5):710-25.
258. Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boilève A, Obrist F, Bordenave C, Garcia P, Michels J, Jemaà M, Kepp O, Castedo M, Kroemer G. Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. *Proc Natl Acad Sci U S A.* 2014 Feb 25;111(8):3020-5.
259. Tufo G, Jones AW, Wang Z, Hamelin J, Tajeddine N, Esposti DD, Martel C, Boursier C, Gallerne C, Migdal C, Lemaire C, Szabadkai G, Lemoine A, Kroemer G, Brenner C. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. *Cell Death Differ.* 2014 May;21(5):685-95.
260. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, Sigl V, Aumayr K, Schmauss G, Fellner N, Handschuh S, Glösmann M, Pasierbek P, Schleder M, Resch GP, Ma Y, Yang H, Popper H, Kenner L, Kroemer G*, Penninger JM (*Corresponding author). A dual role for autophagy in a murine model of lung cancer. *Nat Commun.* 2014;5:3056.
261. Pinton P, Kroemer G. Cancer therapy: Altering mitochondrial properties. *Nat Chem Biol.* 2014 Feb;10(2):89-90.
262. Galluzzi L, Kepp O, Kroemer G. MLKL regulates necrotic plasma membrane permeabilization. *Cell Res.* 2014 Feb;24(2):139-40.

263. Rao S, Yang H, Penninger JM, Kroemer G. Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance. *Autophagy*. 2014 Mar;10(3):529-31.
264. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. *Nat Rev Mol Cell Biol*. 2014 Feb;15(2):81-94.
265. Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. *Cancer Res*. 2014 Jan 15;74(2):436-45.
266. Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. *Oncogene*. 2014 Jul 24;33(30):3894-907.
267. Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariño G, Kepp O, Michaud M, Perfettini JL, Kroemer G, Deutsch E. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. *Cell Death Differ*. 2014 Jan;21(1):92-9.
268. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G. Molecular mechanisms of ATP secretion during immunogenic cell death. *Cell Death Differ*. 2014 Jan;21(1):79-91.
269. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, Galanos C, André F, Kroemer G, Zitvogel L. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. *Cell Death Differ*. 2014 Jan;21(1):69-78.
270. Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. *Cell Death Differ*. 2014 Jan;21(1):59-68.
271. Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, Zitvogel L. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. *Cell Death Differ*. 2014 Jan;21(1):50-8.
272. Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. *Antioxid Redox Signal*. 2014 Mar 1;20(7):1098-116.
273. Carmona-Gutierrez D, Kroemer G, Madeo F. One cell, one love: a journal for microbial research. *Microbial Cell* 1(1): 1-5.
274. Autophagy extends lifespan via vacuolar acidification. Ruckstuhl C, Netzberger C, Entfellner I, Carmona-Gutierrez D, Kickenweiz T, Stekovic S, Gleixner C, Schmid C, Klug L, Hajnal I, Sorgo AG, Eisenberg T, Büttner S, Marin O G, Koziel R, Magnes C, Sinner F, Pieber TR, Jansen-Dürr P, Fröhlich KU, Kroemer G, Madeo F. *Microb Cell*. 2014 May 5;1(5):160-162.
275. Zimmermann A, Bauer MA, Kroemer G, Madeo F, Carmona-Gutierrez D. When less is more: hormesis against stress and disease. *Microb Cell*. 2014 May 5;1(5):150-153.
276. Michaud M, Xie X, Bravo-San Pedro JM, White E, Zitvogel L, Kroemer G. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. *Oncoimmunology*. 2014 Jul 3;3(7):e944047
277. Marino G, Pietrocola F, Madeo F, Kroemer G. Caloric restriction mimetics: non-toxic pharmacological autophagy inducers. *Autophagy*. 2014 Nov 2;10(11):1879-82.

278. Büttner S, Broeskamp F, Sommer C, Markai M, Habernig L, Alavian-Ghavanini A, Carmona-Gutierrez D, Eisenberg T, Michael E, Kroemer G, Tavernarakis N, Sigrist SJ, Madeo F. Spermidine protects against α -synuclein neurotoxicity. *Cell Cycle*. 2014 Dec 15;13(24):3903-8.
279. Bonora M, Bravo-San Pedro JM, Kroemer G*, Galluzzi L, Pinton P. (*Corresponding author). Novel insights into the mitochondrial permeability transition. *Cell Cycle*. 2014 Sep 1;13(17):2666-70.
280. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G*, Galluzzi L. (*Corresponding author). Trial Watch:: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 2014 Jun 1;3:e28694
281. One cell, one love: a journal for microbial research. *Microb Cell*. 2014 Jan 6;1(1):1-5. 2013

2013

282. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science*. 2013 Nov 22;342(6161):971-6.
283. Büttner S, Broeskamp F, Habernig L, Rulli D, Vlachos M, Macchi F, Minois N, Ring J, Eisenberg E, Carmona-Gutierrez D, Reichelt WN, Markaki M, Bammens T, Braun R, Winderickx J, Kroemer G, Baekelandt V, Tavernarakis N, Sigrist SJ, Madeo F. Endonuclease G mediates α -synuclein cytotoxicity in Parkinson's disease models. *EMBO J*. 2013 Nov 27;32(23):3041-54.
284. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. *Nat Rev Drug Discov*. 2013 Nov;12(11):829-46.
285. Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, André F, Kroemer G, Soria JC, Olaussen KA. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. *Cell Cycle*. 2013 Sep 9;12(20).
286. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa G, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon H, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. *Clin Cancer Res*. 2013 Oct 15;19(20):5722-32.
287. Galluzzi L, Kroemer G. Common and divergent functions of Beclin 1 and Beclin 2. *Cell Res*. 2013 Dec;23(12):1341-2
288. Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. *Autophagy*. 2013 Oct;9(10):1624-5
289. Mariño G, Kroemer G. Mechanisms of apoptotic phosphatidylserine exposure. *Cell Res*. 2013 Nov;23(11):1247-8.
290. Lainey E, Wolfromm A, Sukkurwala AQ, Micol JB, Fenaux P, Galluzzi L, Kepp O, Kroemer G. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D 3 in acute myeloid leukemia cells. *Cell Cycle*. 2013 Sep 15;12(18):2978-91.
291. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. *Immunity*. 2013 Aug 22;39(2):211-27.

292. Schmitt S, Saathoff F, Meissner L, Schropp EM, Lichtmanegger J, Schulz S, Eberhagen C, Borchard S, Aichler M, Adamski J, Plesnila N, Rothenfusser S, Kroemer G, Zischka H. A semi-automated method for isolating functionally intact mitochondria from cultured cells and tissue biopsies. *Anal Biochem* 2013 Dec 1;443(1):66-74.
293. Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtel S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. *Cell Death Differ*. 2013 Nov;20(11):1532-45
294. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, Yuan J. Chaperone-mediated autophagy degrades mutant p53. *Genes Dev*. 2013 Aug 1;27(15):1718-30.
295. Spaggiari S, Kepp O, Rello-Varona S, Chaba K, Adjemian S, Pype J, Galluzzi L, Lemaire M, Kroemer G. Antiapoptotic activity of argon and xenon. *Cell Cycle*. 2013 Aug 15;12(16):2636-42.
296. Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. *Oncoimmunology*. 2013 Jun 1;2(6):e24786.
297. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 2013 Jun 1;2(6):e24612.
298. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. *Oncoimmunology*. 2013 Jun 1;2(6):e24568.
299. Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. *Trends Immunol*. 2013 Oct;34(10):471-81.
300. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. *Eur J Cancer*. 2013 Sep;49(14):2965-7.
301. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. *Immunity*. 2013 Jul 25;39(1):74-88.
302. Vilella VR, Esposito S, Maiuri MC, Raia V, Kroemer G, Maiuri L. Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR. *Autophagy*. 2013 Sep;9(9):1431-4
303. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G*, Zitvogel L (*Corresponding author). Crosstalk between ER stress and immunogenic cell death. *Cytokine Growth Factor Rev*. 2013 Aug;24(4):311-8.
304. Cabrera S, Fernández AF, Mariño G, Aguirre A, Suárez MF, Español Y, Vega JA, Laurà R, Fueyo A, Fernández-García MS, Freije JM, Kroemer G, López-Otín C. ATG4B/autophagin-1 regulates intestinal homeostasis and protects mice from experimental colitis. *Autophagy*. 2013 Aug 1;9(8):1188-200.
305. Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *Oncoimmunology*. 2013 May 1;2(5):e24238.
306. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013 Jun 6;153(6):1194-217.
307. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. *Oncoimmunology*. 2013 Apr 1;2(4):e23803.
308. Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G. Fluorescent biosensors for the detection of HMGB1 release. *Methods Mol Biol*. 2013;1004:43-56.

309. Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. *Semin Cancer Biol.* 2013 Oct;23(5):310-22.
310. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology.* 2013 Mar 1;2(3):e23510.
311. Vilella VR, Esposito S, Bruscia EM, Vicinanza M, Cenci S, Guido S, Pettoello-Mantovani M, Carnuccio R, De Matteis MA, Luini A, Maiuri MC, Raia V, Kroemer G*, Maiuri L (*Corresponding author). Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. *Cell Death Differ.* 2013 Aug;20(8):1101-15.
312. Senovilla L, Galluzzi L, Castedo M, Kroemer G. Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. *Ann N Y Acad Sci.* 2013 May;1284:57-61.
313. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. *Cancer Res.* 2013 Jun 15;73(12):3499-510.
314. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. *J Hepatol.* 2013 Sep;59(3):583-94.
315. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. *Immunity.* 2013 Apr 18;38(4):729-41.
316. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G. Cisplatin resistance associated with PARP hyperactivation. *Cancer Res.* 2013 Apr 1;73(7):2271-80.
317. Michels J, Kepp O, Senovilla L, Lissa D, Castedo M, Kroemer G*, Galluzzi L (*Corresponding author). Functions of BCL-X_L at the Interface between Cell Death and Metabolism. *Int J Cell Biol.* 2013:705294. doi: 10.1155/2013/705294. Epub 2013 Feb 28.
318. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Cardiac glycosides and cancer therapy. *Oncoimmunology.* 2013 Feb 1;2(2):e23082.
319. Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax(®). *Oncoimmunology.* 2013 Jan 1;2(1):e23687.
320. Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. *Oncoimmunology.* 2013 Jan 1;2(1):e22409.
321. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. *Oncoimmunology.* 2013 Jan 1;2(1):e22789.
322. Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. *Cell Cycle.* 2013 Mar 15;12(6):877-83
323. Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L. Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. *Antioxid Redox Signal.* 2013 Mar 20. [Epub ahead of print] PubMed PMID: 23394620.

324. Vilella VR, Esposito S, Bruscia EM, Maiuri MC, Raia V, Kroemer G*, Maiuri L (Co-corresponding author). Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect. *Front Pharmacol.* 2013;4:1..
325. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebedzinska M, Marchi S, Patergnani S, Rimessi A, Suski JM, Wojtala A, Wieckowski MR, Kroemer G, Galluzzi L, Pinton P. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. *Cell Cycle.* 2013 Feb 15;12(4):674-83.
326. Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire P, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G. Prognostic value of LIPC in non-small cell lung carcinoma. *Cell Cycle.* 2013 Feb 15;12(4):647-54.
327. Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L, Vitale I, Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. *Oncogene.* 2013 Oct 17;32(42):4995-5004.
328. Boilève A, Senovilla L, Vitale I, Lissa D, Martins I, Métivier D, van den Brink S, Clevers H, Galluzzi L, Castedo M, Kroemer G. Immunosurveillance against tetraploidization-induced colon tumorigenesis. *Cell Cycle.* 2013 Feb 1;12(3):473-9.
329. Valent A, Penault-Llorca F, Cayre A, Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. *Cancer Genet.* 2013 Jan-Feb;206(1-2):37-41.
330. Kepp O, Martins I, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Galluzzi L, Kroemer G. Quantification of cell cycle-arresting proteins. *Methods Mol Biol.* 2013;965:121-42.
331. Vitale I, Jemaà M, Galluzzi L, Metivier D, Castedo M, Kroemer G. Cytofluorometric assessment of cell cycle progression. *Methods Mol Biol.* 2013;965:93-120.
332. Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, Vacchelli E, Chatelut E, Castedo M, Kroemer G. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. *Cell Cycle.* 2013 Feb 1;12(3):417-21.
333. Bauer MA, Carmona-Gutiérrez D, Ruckenstuhl C, Reisenbichler A, Megalou EV, Eisenberg T, Magnes C, Jungwirth H, Sinner FM, Pieber TR, Fröhlich KU, Kroemer G, Tavernarakis N, Madeo F. Spermidine promotes mating and fertilization efficiency in model organisms. *Cell Cycle.* 2013 Jan 15;12(2):346-52.
334. Jemaà M, Galluzzi L, Kepp O, Castedo M, Rello-Varona S, Vitale I, Kroemer G. Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations. *Cell Cycle.* 2013 Jan 1;12(1):183-90.
335. Niso-Santano M, Shen S, Adjemian S, Malik SA, Mariño G, Lachkar S, Senovilla L, Kepp O, Galluzzi L, Maiuri MC, Kroemer G. Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. *Autophagy.* 2013 Mar;9(3):415-7.
336. Fimia GM, Kroemer G, Piacentini M. Molecular mechanisms of selective autophagy. *Cell Death Differ.* 2013 Jan;20(1):1-2.
337. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol.* 2013;31:51-72.
338. Büttner S, Faes L, Reichelt WN, Broeskamp F, Habernig L, Benke S, Kourtis N, Ruli D, Carmona-Gutierrez D, Eisenberg T, D'hooge P, Ghillebert R, Franssens V, Harger A, Pieber TR, Freudenberger P, Kroemer G, Sigrist SJ, Winderickx J, Callewaert G, Tavernarakis N, Madeo F. The Ca(2+)/Mn(2+) ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α -synuclein toxicity in Parkinson's disease models. *Cell Death Differ.* 2013 Mar;20(3):465-77.

339. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E. Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance. *Cancer Microenviron.* 2013 Aug;6(2):147-57
340. Lainey E, Wolffromm A, Enot D, Galluzzi L, Sebert M, Bouteloup C, Leroy C, Micol JB, de Botton S, Fenaux P, Kroemer G. Synergistic cytotoxic and cytostatic effects of azacytidine and erlotinib in acute myeloid leukemia. *Oncogene* 2013 Sep 12;32(37):4331-42
341. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G*, Zitvogel L (*Corresponding author). Crosstalk between ER stress and immunogenic cell death. *Cytokines Growth Factor Rev.* 2013 Aug;24(4):311-8
342. Martel C, Allouche M, Esposti DD, Fanelli E, Boursier C, Henry C, Chopineau J, Calamita G, Kroemer G, Lemoine A, Brenner C. GSK3-mediated VDAC phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation. *Hepatology.* 2013 Jan;57(1):93-102.
343. Yao Z, Jones AW, Fassone E, Sweeney MG, Lebedzinska M, Suski JM, Wieckowski MR, Tajeddine N, Hargreaves IP, Yasukawa T, Tufo G, Brenner C, Kroemer G, Rahman S, Szabadkai G. PGC-1 β mediates adaptive chemoresistance associated with mitochondrial DNA mutations. *Oncogene.* 2013 May 16;32(20):2592-600
344. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. *OncoImmunology* 2013 Oct 1;2(10):e26536.
345. Semeraro M, Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. *OncoImmunology* 2013 Nov 1;2(11):e26494
346. Aranda F, Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. *OncoImmunology* 2013 Dec 1;2(12):e26621
347. Kepp O, Galluzzi L, Kroemer G. Immune effectors required for the therapeutic action of vorinostat. *OncoImmunology* 2013 Nov 1;2(11):e27157

2012

348. Zitvogel L, Hannani D, Aymeric L, Kepp O, Martins I, Kroemer G. [Antitumoral immunization during cancer chemotherapy]. *Bull Acad Natl Med.* 2012 Jun;196(6):1075-86.
349. Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G. Immunosurveillance against cancer-associated hyperploidy. *Oncotarget.* 2012 Nov;3(11):1270-1. PubMed PMID: 23174699.
350. Zitvogel L, Hannani D, Aymeric L, Kepp O, Martins I, Kroemer G. [Antitumoral immunization during cancer chemotherapy]. *Bull Acad Natl Med.* 2012 Jun;196(6):1075-86.
351. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, Kroemer G. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. *Oncoimmunology.* 2012 Dec 1;1(9):1640-1642.
352. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. *Oncoimmunology.* 2012 Dec 1;1(9):1557-1576.
353. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. *Oncoimmunology.* 2012 Nov 1;1(8):1323-1343.
354. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. *Oncoimmunology.* 2012 Nov 1;1(8):1223-1225.

355. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. *Nat Rev Mol Cell Biol.* 2012 Dec;13(12):780-8
356. Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G. Immunosurveillance against cancer-associated hyperploidy. *Oncotarget.* 2012 Nov;3(11):1270-1.
357. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. *Oncoimmunology.* 2012 Oct 1;1(7):1111-1134.
358. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. *Oncoimmunology.* 2012 Sep 1;1(6):894-907.
359. Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. *Cell Cycle.* 2012 Nov 1;11(21):4079-92.
360. Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, Souquere S, Mariño G, Lachkar S, Senovilla L, Galluzzi L, Kepp O, Pierron G, Maiuri MC, Hikita H, Kroemer R, Kroemer G. Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity. *Mol Cell.* 2012 Dec 14;48(5):667-80.
361. Pietrocola F, Mariño G, Lissa D, Vacchelli E, Malik SA, Niso-Santano M, Zamzami N, Galluzzi L, Maiuri MC, Kroemer G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. *Cell Cycle.* 2012 Oct 15;11(20):3851-60.
362. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. *Circ Res.* 2012 Oct 12;111(9):1198-207.
363. Minois N, Carmona-Gutierrez D, Bauer MA, Rockenfeller P, Eisenberg T, Brandhorst S, Sigrist SJ, Kroemer G, Madeo F. Spermidine promotes stress resistance in *Drosophila melanogaster* through autophagy-dependent and -independent pathways. *Cell Death Dis.* 2012 Oct 11;3:e401.
364. Senovilla L, Vitale I, Martins I, Tailler M, Paillet C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, Shen S, Mariño G, Criollo A, Boilève A, Job B, Ladoire S, Ghiringhelli F, Sistigu A, Yamazaki T, Rello-Varona S, Locher C, Poirier-Colame V, Talbot M, Valent A, Berardinelli F, Antoccia A, Ciccocioppo F, Fimia GM, Piacentini M, Fueyo A, Messina NL, Li M, Chan CJ, Sigl V, Pourcher G, Ruckenstein C, Carmona-Gutierrez D, Lazar V, Penninger JM, Madeo F, López-Otín C, Smyth MJ, Zitvogel L, Castedo M, Kroemer G. An immunosurveillance mechanism controls cancer cell ploidy. *Science.* 2012 Sep 28;337(6102):1678-84
365. Klionsky DJ, Abdalla FC, ... Kroemer G, ... Zong WX, Zorzano A, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy.* 2012 Apr;8(4):445-544.
366. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. *Oncoimmunology.* 2012 Aug 1;1(5):699-716.
367. Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines? *Oncoimmunology.* 2012 Aug 1;1(5):579-580.
368. Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E, Robert T, Ripoche H, Jägemann N, Paccard C, Servant N, Hupé P, Lazar V, Dessen P, Barillot E, Zischka H, Madeo F, Kroemer G. Independent transcriptional reprogramming and apoptosis induction by cisplatin. *Cell Cycle.* 2012 Sep 15;11(18):3472-80.
369. Castedo M, Senovilla L, Vitale I, Kroemer G. Tetraploid cancer cell precursors in ovarian carcinoma. *Cell Cycle.* 2012 Sep 1;11(17):3157-8.

370. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, Guido S, Pettoello-Mantovani M, Carnuccio R, Scholte B, De Matteis A, Maiuri MC, Raia V, Luini A, Kroemer G*, Maiuri L (*Corresponding author). Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on $\Delta F508$ cystic fibrosis transmembrane conductance regulator. *Autophagy*. 2012 Nov;8(11):1657-72.
371. Galluzzi L, Vitale I, Senovilla L, Olausson KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G. Prognostic impact of vitamin B6 metabolism in lung cancer. *Cell Rep*. 2012 Aug 30;2(2):257-69
372. Cano CE, Sandí MJ, Hamidi T, Calvo EL, Turrini O, Bartholin L, Loncle C, Secq V, Garcia S, Lomberk G, Kroemer G, Urrutia R, Iovanna JL. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. *EMBO Mol Med*. 2012 Sep;4(9):964-79.
373. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, Zitvogel L, Kepp O, Kroemer G. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. *Sci Transl Med*. 2012 Jul 18;4(143):143ra99.
374. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. *Oncoimmunology*. 2012 Jul 1;1(4):493-506.
375. Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. *Oncoimmunology*. 2012 Jul 1;1(4):407-408.
376. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. *Oncoimmunology*. 2012 May 1;1(3):393-395.
377. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard SP, Tartour E. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. *Oncoimmunology*. 2012 May 1;1(3):326-333.
378. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. *Oncoimmunology*. 2012 May 1;1(3):306-315.
379. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, Schlemmer FD, Menger L, Sukkurwala AQ, Adjemian S, Martins I, Michaud M, Dunant A, Kepp O, Brambilla E, Soria JC, Zitvogel L, Kroemer G. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. *Oncoimmunology*. 2012 May 1;1(3):271-278.
380. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology*. 2012 Mar 1;1(2):179-188.
381. Kroemer G, Fridman WH, Sautès-Fridman C, Zitvogel L. The European Academy of Tumor Immunology: Bridging fields, continents and generations. *Oncoimmunology*. 2012 Mar 1;1(2):127-128
382. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. *Oncoimmunology*. 2012 Jan 1;1(1):28-37.

- 383.39: Zitvogel L, Kroemer G. OncoImmunology: a new journal at the frontier between oncology and immunology. *Oncoimmunology*. 2012 Jan 1;1(1):1-2.
384. Paoletti A, Raza SQ, Voisin L, Law F, Pipoli da Fonseca J, Caillet M, Kroemer G, Perfettini JL. Multifaceted roles of purinergic receptors in viral infection. *Microbes Infect*. 2012 Nov;14(14):1278-83.
385. Carmona-Gutierrez D, Kroemer G, Madeo F. When death was young: an ancestral apoptotic network in bacteria. *Mol Cell*. 2012 Jun 8;46(5):552-4.
386. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, Poirier-Colame V, Andreiuolo F, Galluzzi L, White E, Rosenfeldt M, Ryan KM, Zitvogel L, Kroemer G. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. *Autophagy*. 2012 Aug;8(8):1175-84.
387. Jemaà M, Galluzzi L, Kepp O, Boilève A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antocchia A, Castedo M, Vitale I, Kroemer G. Preferential killing of p53-deficient cancer cells by reversine. *Cell Cycle*. 2012 Jun 1;11(11):2149-58.
388. Galluzzi L, Kroemer G. Autophagy mediates the metabolic benefits of endurance training. *Circ Res*. 2012 May 11;110(10):1276-8.
389. Carmona-Gutierrez D, Sommer C, Andryushkova A, Kroemer G, Madeo F. A higher spirit: avoiding yeast suicide during alcoholic fermentation. *Cell Death Differ*. 2012 Jun;19(6):913-4.
390. Bennetzen MV, Mariño G, Pultz D, Morselli E, Færgeman NJ, Kroemer G, Andersen JS. Phosphoproteomic analysis of cells treated with longevity-related autophagy inducers. *Cell Cycle*. 2012 May 1;11(9):1827-40.
391. Rodriguez DA, Zamorano S, Lisbona F, Rojas-Rivera D, Urra H, Cubillos-Ruiz JR, Armisen R, Henriquez DR, Cheng EH, Letek M, Vaisar T, Irrazabal T, Gonzalez-Billault C, Letai A, Pimentel-Muiños FX, Kroemer G, Hetz C. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1 α . *EMBO J*. 2012 Apr 17;31(10):2322-35.
392. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di Virgilio F. Expression of P2X7 receptor increases in vivo tumor growth. *Cancer Res*. 2012 Jun 15;72(12):2957-69.
393. Jemaà M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, Mariño G, Malik SA, Rello-Varona S, Lissa D, Antocchia A, Tailler M, Schlemmer F, Harper F, Pierron G, Castedo M, Kroemer G. Selective killing of p53-deficient cancer cells by SP600125. *EMBO Mol Med*. 2012 Jun;4(6):500-14.
394. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. *Nat Immunol*. 2012 Mar 18;13(4):343-51.
395. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. *Cancer Res*. 2012 Jun 1;72(11):2757-67.
396. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Non-apoptotic functions of apoptosis-regulatory proteins. *EMBO Rep*. 2012 Apr 2;13(4):322-30.
397. Hannani D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L. Harnessing $\gamma\delta$ T cells in anticancer immunotherapy. *Trends Immunol*. 2012 May;33(5):199-206.
398. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. *Autophagy*. 2012 Mar;8(3):413-5.
399. Galluzzi L, Kepp O, Kroemer G. Reverse Warburg: straight to cancer. *Cell Cycle*. 2012 Mar 15;11(6):1059.

400. Niso-Santano M, Criollo A, Malik SA, Michaud M, Morselli E, Mariño G, Lachkar S, Galluzzi L, Maiuri MC, Kroemer G. Direct molecular interactions between Beclin 1 and the canonical NFκB activation pathway. *Autophagy*. 2012 Feb 1;8(2):268-70.
401. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. *Nat Rev Drug Discov*. 2012 Feb 3;11(3):215-33.
402. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. *Cell Death Dis*. 2012 Jan 26;3:e262.
403. Tarakhovskiy AS, Kroemer G. Innate immunity. *Curr Opin Immunol*. 2012 Feb;24(1):1-2.
404. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. *EMBO J*. 2012 Jan 17;31(5):1055-7.
405. Criollo A, Chereau F, Malik SA, Niso-Santano M, Mariño G, Galluzzi L, Maiuri MC, Baud V, Kroemer G. Autophagy is required for the activation of NFκB. *Cell Cycle*. 2012 Jan 1;11(1):194-9. doi:
406. Rello-Varona S, Lissa D, Shen S, Niso-Santano M, Senovilla L, Mariño G, Vitale I, Jemaá M, Harper F, Pierron G, Castedo M, Kroemer G. Autophagic removal of micronuclei. *Cell Cycle*. 2012 Jan 1;11(1):170-6.
407. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Grujil T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. *J Transl Med*. 2011 Dec 14;9(1):214.
408. Galluzzi L, Morselli E, Kepp O, Vitale I, Younes AB, Maiuri MC, Kroemer G. Evaluation of rapamycin-induced cell death. *Methods Mol Biol*. 2012;821:125-69.
409. Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, Baud V, Billot K, Fenaux P, Galluzzi L, Boehrer S, Kroemer G, Kepp O. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. *Oncogene*. 2012 Jul 26;31(30):3536-46.
410. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? *Autophagy*. 2012 Jan;8(1):1-3..

Autres articles (articles publiés dans des revues professionnelles ou techniques, etc.)

None.

2. Ouvrages

Monographies et ouvrages scientifiques, éditions critiques, traductions

None.

Direction / édition scientifique

Principles of Oncoimmunology. Eds. L. Zitvogel & G. Kroemer. Springer, in press

Chapitres d'ouvrage

None.

Thèses publiées / éditées

None.

3. Colloques / congrès, séminaires de recherche

Éditions d'actes de colloques / congrès

None.

Articles publiés dans des actes de colloques / congrès

None.

Autres produits présentés dans des colloques / congrès et des séminaires de recherche

None.

4. Développements instrumentaux et méthodologiques

Prototypes et démonstrateurs

None.

Plateformes et observatoires

We built the Metabolomics platform, as well as the Cell Biology platform at Gustave Roussy Cancer Campus.

...

5. Produits et outils informatiques

Logiciels

None.

Bases de données / cohortes

None.

Corpus

None.

Outils présentés dans le cadre de compétitions de solveurs

None.

Outils d'aide à la décision

None.

...

6. Brevets, licences et déclarations d'invention

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS	WO2016092041 (A1)	2016-06-16	KROEMER GUIDO [FR] PERFETTINI JEAN-LUC [FR] GOUGEON MARIE-LISE [FR] ALLOUCH AWATEF [FR] PIACENTINI MAURO [IT]
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF	US2016250249 (A1)	2016-09-01	KROEMER GUIDO [FR] MARINO GUILLERMO [FR] PIETROCOLA FEDERICO [FR]
Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders	US2016031955 (A1)	2016-02-04	MODJTAHEDI NAZANINE [FR] KROEMER GUIDO [FR]
COMBINATIONS FOR THE TREATMENT OF CANCER	WO2014020043 (A1)	2014-02-06	SIEMEISTER GERHARD [DE] BADER BENJAMIN [DE] WENGNER ANTJE [DE] MUMBERG DOMINIK [DE] SCHULZE VOLKER [DE] KROEMER GUIDO [FR] VITALE ILIO [IT] JEMAA MOHAMED [TN]
COMBINATIONS FOR THE TREATMENT OF CANCER	WO2014020041 (A1)	2014-02-06	SIEMEISTER GERHARD [DE] BADER BENJAMIN [DE] WENGNER ANTJE MARGRET [DE] MUMBERG DOMINIK [DE] KOPFITZ MARCUS [DE] KLAR ULRICH [DE] KROEMER GUIDO [FR] VITALE ILIO [IT] JEMAA MOHAMED [TN]
SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER	US2015185202 (A1)	2015-07-02	PERFETTINI JEAN-LUC [FR] KROEMER GUIDO [FR] DEUTSCH ERIC [FR]
COMBINED THERAPY FOR CYSTIC FIBROSIS	US2015328203 (A1)	2015-11-19	MAIURI LUIGI [IT] RAIA VALERIA [IT] BORELLA FABIO [IT] KROEMER GUIDO [IT]
PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF	US2013281313 (A1)	2013-10-24	GALLUZZI LORENZO [FR] HAREL-BELLAN ANNICK [FR] KROEMER GUIDO [FR] OLUSSEN KEN [FR] SORIA JEAN-CHARLES [FR]
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS	US2013156791 (A1)	2013-06-20	PERFETTINI JEAN-LUC [FR] KROEMER GUIDO [FR] GOUGEON MARIE-LISE [FR] PIACENTINI MAURO [IT]
KITS AND METHODS FOR DETECTING THE ABILITY TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT	WO2012007783 (A8); WO2012007783 (A1)	2012-01-19	ZITVOGEL LAURENCE [FR] KROEMER GUIDO [FR] DELAHAYE NICOLAS [FR]
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject	EP2806034 (A1)	2014-11-26	ZITVOGEL LAURENCE [FR] KROEMER GUIDO [FR] MA YUTING [CN] KEPP OLIVER [FR] DELAHAYE NICOLAS [US]
COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT	US2013156790 (A1); US8865653 (B2)	2013-06-20	ZITVOGEL LAURENCE [FR] KROEMER GUIDO [FR]
COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT	US8828944 (B2); US2013052160 (A1)	2013-02-28	ZITVOGEL LAURENCE [FR] KROEMER GUIDO [FR] DELAHAYE NICOLAS [BE] MA YUTING [FR] KEPP OLIVER [FR]
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS	WO2016092041 (A1)	2016-06-16	KROEMER GUIDO [FR] PERFETTINI JEAN-LUC [FR] GOUGEON MARIE-LISE [FR] ALLOUCH AWATEF [FR] PIACENTINI MAURO [IT]
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF	US2016250249 (A1)	2016-09-01	KROEMER GUIDO [FR] MARINO GUILLERMO [FR] PIETROCOLA FEDERICO [FR]
Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders	US2016031955 (A1)	2016-02-04	MODJTAHEDI NAZANINE [FR] KROEMER GUIDO [FR]
COMBINATIONS FOR THE TREATMENT OF CANCER	WO2014020043 (A1)	2014-02-06	SIEMEISTER GERHARD [DE] BADER BENJAMIN [DE] WENGNER ANTJE [DE] MUMBERG DOMINIK [DE] SCHULZE VOLKER [DE] KROEMER GUIDO [FR] VITALE ILIO [IT] JEMAA MOHAMED [TN]
COMBINATIONS FOR THE TREATMENT OF CANCER	WO2014020041 (A1)	2014-02-06	SIEMEISTER GERHARD [DE] BADER BENJAMIN [DE] WENGNER ANTJE MARGRET [DE] MUMBERG DOMINIK [DE] KOPFITZ MARCUS [DE] KLAR ULRICH [DE] KROEMER GUIDO [FR] VITALE ILIO [IT] JEMAA MOHAMED [TN]

7. Rapports d'expertises techniques, produits des instances de normalisation

None.

8. Produits des activités didactiques

Ouvrages

None.

E-learning, moocs, cours multimedia, etc.

None.

9. Produits destinés au grand public

Émissions radio, TV, presse écrite

None.

Produits de vulgarisation : articles, interviews, éditions, vidéos, etc.

Interviews dans Le Monde (2014) et le Journal de Dimanche (2016).

Produits de médiation scientifique

None.

Débats science et société

None.

10. Autres produits propres à une discipline

Créations artistiques théorisées

None.

Mises en scènes

None

Films

None

...

II. ACTIVITÉS DE RECHERCHE ET INDICES DE RECONNAISSANCE

La liste de ces activités n'a pas à être exhaustive. On mettra en évidence les activités les plus significatives en termes de rayonnement et d'attractivité, d'interaction avec l'environnement et d'implication dans la formation par la recherche.

1. Activités éditoriales

Participation à des comités éditoriaux (revues, collections)

Major editorial appointments de Guido Kroemer

Dates	Position	Journal (Publisher)	City, Country
2010-2016	Founding Editor-in-Chief	Cell Death & Disease (Springer/Nature)	London, UK
2012-	Founding Editor-in-Chief	OncoImmunology (Taylor & Francis)	Philadelphia, PA, USA
2013-2017	Founding Editor-in-Chief	Microbial Cell (Shared Science Publishers)	Graz, Austria
2014-	Founding Editor-in-Chief	Molecular & Cellular Oncology (Taylor & Francis)	Philadelphia, PA, USA
2017-	Deputy Editor	Cell Death & Disease (Springer/Nature)	London, UK
2017-	Deputy Editor	Cell Death & Differentiation (Springer/Nature)	London, UK
2017-	Founding Editor-in-Chief	Cell Stress (Shared Science Publishers)	Graz, Austria

Other editorial appointments since 2012

Dates	Journal (Publisher)	Position
1998-2016	Cell Death and Differentiation (Springer/Nature)	Receiving Editor
2005-2016	Autophagy (Taylor & Francis)	Associate Editor
2007-	Proceedings of the National Academy of Sciences USA	Guest Editor
2007-	Cell Cycle (Landes Bioscience, Taylor & Francis)	Editorial Board Member
2008-	Aging-US (Impact Journals)	Editorial Board Member
2008-	Biochemical and Biophysical Research Communications (Elsevier)	Editor
2009-	Cancer Research (American Association for Cancer Research)	Editorial Board Member
2009-2017	Oncogene (Springer/Nature)	Reviews Editor
2009-	Journal of Molecular Cell Biology (Oxford)	Associate Editor
2010-	American Journal of Cancer Research (e-Century Publishing)	Founding Editor
2010-	Oncotarget (Impact Journals)	Founding Editor
2011-	Molecular Oncology (Elsevier)	Editorial Board Member
2011-2013	Frontiers in Oncology (Frontiers, Lausanne, Switzerland)	Specialty Chief Editor
2012-2013	Seminars in Immunopathology (Springer)	Advisory Board Member
2013-	EMBO Molecular Medicine (Wiley)	Editorial Board Member
2013-	Molecular & Cellular Biology (American Society for Microbiology)	Editorial Board Member
2013-	Science Signaling (American Assoc. for the Advancement of Science)	Reviewing Editor
2015-	Oncogenesis (Springer/Nature)	Editorial Board Member
2015-	Cell Research (Springer/Nature)	Editorial Board Member
2015-	Cell Discovery (Springer/Nature)	Editorial Board Member
2016-	Signal Transduction and Targeted Therapy (Springer/Nature)	Editorial Board Member

Direction de collections et de séries depuis 2012

Guest Editor of Special Issues: Cell Death Differentiation (Nature Publishing Group) in 2013, 2015, 2016; Circulation Research (American Heart Association) in 2013 and 2016; Current Opinion in Immunology (Elsevier) in 2012; Cytokine and Growth Factor Reviews in 2013; Experimental Cell Research (Academic Press) in 2012; Immunological Reviews (Munksgaard-Springer) in 2017; Journal of Clinical Investigation (Rockefeller University Press) in 2015; Methods in Enzymology (Elsevier) in 2014 (two volumes) and 2017 (two volumes); Methods in Molecular Biology (Springer) in 2013; Seminars in Cellular and Developmental Biology (Elsevier) in 2014

2. Activités d'évaluation

Responsabilités au sein d'instances d'évaluation

Scientific Boards

Date	Organization	Position
------	--------------	----------

2005-present	Nomenclature Committee on Cell Death (NCCD)	President
2007-present	Italian Association for Cancer Research, Milano, Italy	Member, Review Team
2009-2015	Worldwide Innovative Networking (WIN), Paris, France	Scientific Advisory Board
2010-2015	Cancéropôle Ile-de-France	Member, Organizing Committee
2011-2015	World Immunotherapy Council of the Society for the Immunotherapy of Cancer (SITC)	Scientific Advisory Board
2011-present	Institut Gustave Roussy, Committee of Co-Directors	Member
2011-present	Committee on Publication Ethics (COPE)	Member
2012-present	Institute for Medical Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria	Scientific Advisory Board
2012-2015	Targeted Anticancer Therapies (TAT)	Scientific Advisory Board
2013	Selection Committee for the Scientific Award Foundation AstraZeneca – Oncology, Bruxelles, Belgium	Member
2013	AACR Princess Takamatsu Lectureship Award Committee	Member
2013	AACR Annual Meeting, Program Committee	Member
2014	AACR-CIMM Chairperson-Elect Nominating Committee	Member
2014-2015	AACR-Millennium Fellowship in Lymphoma Research	Scientific Review Committee
2015-present	FINBA (Fundación para la Investigación Biosanitaria en Asturias)	Chairman of SAB
2015-present	Regina Elena National Cancer Research Institute, Rome, Italy	Scientific Advisory Board
2015-present	European Alliance for Immuno-Oncology (EAIO)	Scientific Advisory Board
2015-present	European Research Institute on Cystic Fibrosis (Milan, Italy)	Scientific Advisory Board
2016-present	Center for Geroscience, brain health and metabolism (Chile)	Scientific Advisory Board
2016-present	Cancer Immunotherapy (CIMT, Mainz, Germany)	Scientific Advisory Board
2017	AACR Annual Meeting (Washington), Program Committee	Member
2017	ESMO/EACR Congress (Barcelona) Program Committee	Member

Évaluation d'articles et d'ouvrages scientifiques

See editorial activities. In addition, I have been reviewing articles for all major scientific journals.

Évaluation de laboratoires (type Hceres)

None

Évaluation de projets de recherche

None

3. Activités d'expertise scientifique

Activités de consultant

Appointments in Pharmaceutical Industry and Biotechnology

Dates	Title	Organization	City, Country
2009-present	Advisor, Discovery Oncology Board	Bayer Healthcare	Berlin, Germany
2014-2015	Oncology Scientific Advisory Board	Hoffmann-La Roche Ltd.	Basel, Switzerland
2015-2017	Chairman of Scientific Advisory Board	Medicenna Therapeutics	Vanvouver, Canada
2015-present	Scientific Advisory Board	Lytix Ltd.	Oslo, Norway
2015-present	Board of Directors/Executive Board	Bristol Meyers Squibb Foundation	Paris, France
2016-present	Permanent consultant	Genmab SA	Kopenhagen, Denmark
2016-present	Founder	EverImmune (Biotech company)	Paris, France

Participation à des instances d'expertises (type Anses) ou de normalisation

None.

Expertise juridique

Idem.

4. Organisation de colloques / congrès

Organization of International Conferences since 2012

Date	Role	Meeting	City, Country
2012, June	President	Euroconference on Death, Danger, Inflammation & Immunity	Paris, France
2013, July	President	3 rd International Conference on Immunochemotherapy	Paris, France
2013, Sept.	President	21 st ECDO Conference on Cell Death in Biomedicine	Paris, France
2014, Jan.	Organizer	Metabolism as therapeutic target (ERI-ICP Conference)	Luxembourg
2014, May	Organizer	Keystone Conference on Autophagy	Austin, Texas, USA
2014, July	Organizer	EATI Conference on Anticancer Immunosurveillance	Paris, France
2015, April	Organizer	4 th International Conference on Immunochemotherapy	Philadelphia, PA, USA
2014, July	Organizer	EATI Conference on Microbiome and Immunopathologies	Paris, France
2015, Sept	Co-Organizer	AACR/CIMT/CRI/EATI Conference on Tumor Immunology	New York, NY, USA
2015, Oct	Co-Organizer	Advances in Neurosciences for Medical Innovation (Servier)	Chantilly, France
2016, July	Organizer	EATI Conference on Novel Checkpoint Blockers	Paris, France
2016, Oct	Organizer	EMBO Conference on Cancer Cell Signaling and Metabolism	Bilbao, Spain
2016, Sept	Co-Organizer	AACR/CIMT/CRI/EATI Conference on Tumor Immunology	New York, NY, USA
2017, March	Organizer	PACRI Conference on Cancer Research	Paris, France
2017, Sept	Co-Organizer	AACR/CIMT/CRI/EATI Conference on Tumor Immunology	Mainz, Germany

5. Post-doctorants et chercheurs accueillis

On précisera ici les faits observables pertinents pour l'évaluation (nombre, publications, financements ...)

6. Interactions avec les acteurs socio-économiques

Contrats de R&D avec des industriels

Partner	Contract type	Budget	duration (month)	start date	project title
BAYER PHARMA AG	Collaboration agreement	342 391,00 €	26	30-Nov-15	Screening of anticancer molecules for their capacity to induce a signature of immunogenic cell death
GENENTECH Inc	Collaboration agreement	167 000,00 €	6	27-Oct-11	Determination of the capacity of anti-cancer targeted agents to induce immunogenic cell death
GlaxoSmithKline LLC	Collaboration agreement	325 000,00 €	24	19-Nov-12	Determination of the capacity of anti-cancer targeted agents to induce

					<i>immunogenic cell death</i>
GlaxoSmithKline LLC	Collaboration agreement		21	14-Feb-13	<i>To amend the Research Collaboration Agreement dated November 15, 2012 to include in the Research Program lapatinib, trastuzumab</i>
GlaxoSmithKline LLC	Collaboration agreement		7	06-Apr-14	<i>modifications de l'annexe scientifique = programme des travaux de recherche pour définir TASK 3</i>
Lytix Biopharma AS	Collaboration agreement	290 000,00 €	20	06-Jun-14	<i>Mechanistic exploration of the cytotoxic activity of LTX-315</i>
Lytix Biopharma AS	Collaboration agreement	100 000,00 €	12	05-Feb-16	<i>Mechanistic studies of cell lysis by LTX-401 vs LTX-315</i>
Lytix Biopharma AS	Collaboration agreement	120 000,00 €	18	02-Apr-16	<i>Avenant n°2 Biotek2021 - Mechanistic exploration of the cytotoxic activity of DTT-peptides</i>
Pharma Mar S.A.	Service agreement	24 390,00 €	10	04-Jun-15	<i>Screening of anticancer molecules for their capacity to induce a signature of immunogenic cell death</i>
Pharma Mar S.A.	Service agreement	60 976,00 €	9	25-Jan-16	<i>Screening of anticancer molecules for their capacity to induce a signature of immunogenic cell death Research program 2</i>
Pharma Mar S.A.	Service agreement	129 268,00 €	12	25-Nov-16	<i>Screening of anticancer molecules for their capacity to induce a signature of immunogenic cell death Extend the agreement and</i>
Vasculox	Collaboration agreement	84 977,00 €	14	16-May-16	<i>Study 1 - In vivo effects of anti-CD47 antibodies on breast cancer</i>
TIOMA Therapeutics Inc.	Collaboration agreement	225 458,00 €	8	21-Apr-17	<i>Supplementary project programme : "In vivo effects of anti-CD47 antibodies on breast cancer"</i>

Bourses Cifre

None.

Créations de laboratoires communs avec une / des entreprise(s)

None.

Création de réseaux ou d'unités mixtes technologiques

None.

Créations d'entreprises, de start-up

In mid-2016 Guido Kroemer co-founded the BioTech company EverImmune.

7. Contrats de recherche financés par des institutions publiques ou caritatives

Contrats européens (ERC, H2020, etc.) et internationaux (NSF, JSPS, NIH, Banque mondiale, FAO , etc.)

Idem.

Contrats nationaux (ANR, PHRC, FUI, INCA, etc.)

Idem.

Contrats avec les collectivités territoriales

Idem.

Contrats financés dans le cadre du PIA

Idem.

Contrats financés par des associations caritatives et des fondations (ARC, FMR, FRM, etc.)

Idem.

8. Indices de reconnaissance

On s'en tiendra aux indices de reconnaissance les plus significatifs pour le rayonnement et l'attractivité de l'unité de recherche.

Prix de Guido Kroemer 2012-2017

Year	Name	Awarding Institution
2012	Léopold Griffuel Prize	Association for Cancer Research, Paris, France
2013	ERC Advanced Investigator Award (2 500 000 €)	European Research Council (ERC), Bruxelles, European Union
2014	Mitjavile Prize	National Academy of Medicine, Paris, France
2015	Most cited European cell biologist 2007-2013 Ohdang Distinguished Award	Ranking elaborated by Labtimes (2015, Issue 5, p. 38) Pharmaceutical Society of Korea, Seoul, South Korea
2016	Galien Award for Pharmacological Research International Prize for Oncology Ramiro Carregal EFIS Lecture Award	Prix Galien de la Recherche Pharmaceutique, Paris, France Rosaleda Foundation, Santiago de Compostela, Spain European Federation of Immunol. Societies, Innsbruck, Austria
2017	Grand Prix Claude Bernard Brupbacher Prize for Cancer Research (shared with Laurence Zitvogel)	Science and Medicine Prize of the City of Paris, France Charles Rudolphe Brupbacher Foundation, Zurich, Switzerland

Distinctions de Guido Kroemer 2012-2017

Year	Name	Awarding Institution
2012	Most cited European in cancer research 1998-2011	Ranking published by Labtimes (2012, Issue 1, p. 42)
2013	Most cited European immunologist 1996-2012 1 st top rank scientist in biomedicine worldwide 1996-2011 with regard to the number of highly cited papers (>100 times) signed as last author	Ranking published by Labtimes (2013, Issue 6, p. 38) Ranking published by Eur J Clin Invest 2013; 43(12):1339-1365 http://www.mapofscience.com/?page_id=761
2015	Most cited European cell biologist 2007-2013 Foreign adjunct professor (honorary position)	Ranking elaborated by Labtimes (2015, Issue 5, p. 38) Karolinska Institute & Hospital, Stockholm, Sweden
2016	ISI "Highly cited researcher" in four areas: 1. Biology & Biochemistry 2. Immunology 3. Molecular Biology & Genetics 4. Pharmacology & Toxicology Honorary professor	Institute for Scientific Information (ISI) - Thomson-Reuters, Philadelphia, USA; http://isihighlycited.com/
2017	Doctor honoris causa	Suzhou Institute for Systems Medicine, Suzhou, China Faculty of Medicine, University of Rome Tor Vergata, Italy

Responsabilités dans des sociétés savantes de Guido Kroemer 2012-2017

Year	Name	Awarding Institution
2000	Elected EMBO member	European Molecular Biology Organization, Heidelberg, Germany
2007	Elected foreign member Elected member (Academician)	Austrian Academy of Sciences, Vienna, Austria German Academy of Sciences (Leopoldina), Halle, Germany
2008	Elected member (Academician)	Academia Europaea, London, UK
2009	Elected member (Academician)	European Academy of Sciences and Arts, Salzburg, Austria
2010	Founding president	European Academy of Cancer Sciences, Amsterdam, Netherlands
2015	Senior member	European Academy of Tumor Immunology, Paris, France Institut Universitaire de France, Paris, France

Invitations honorifiques de Guido Kroemer

Year	Name	Awarding Institution/Conference
2012	Lambertsen Honorary Lecture	University of Pennsylvania, Philadelphia, PA, USA
	Ramalingaswami Mem. Lecture	National Institute of Immunology, New Delhi, India
	Retreat Lecture	Lautenberg Research Center, Hebrew University, Jerusalem, Israel
	EPHAR Lecture	Federation of European Pharmacology Societies (EPHAR), Bern, Switzerland
	Keynote	International Conference on Cell Death in Cancer, St. Malo, France
	Keynote	ARVO Conference (Assoc. for Research in Vision and Ophthalmology), Miami, FL
	Keynote	European Association for Cancer Research (EACR), Amsterdam, Netherlands
2013	Distinguished Guest Lecture	Barts Cancer Institute, London, UK
	Keynote	Gordon Conference on Apoptotic Cell Recognition, Biddeford, Maine, USA
	Closing Keynote	Annual Meeting of the Canadian Cancer Immunotherapy Consortium, Toronto
	Keynote	Annual Meeting of the Cancer Immunotherapy Consortium, Washington, USA
2014	Distinguished Ludwig Lecture	Ludwig Institute for Cancer Research, Lausanne, Switzerland
	Keynote	Metabolism & Disease Conference, Luxembourg
	Keynote	Conference on Cancer Immunology and Immunotherapy, Pamplona, Spain
	Karolinska Research Lecture	Medical Nobel Institute and Nobel Assembly, Stockholm, Sweden
	Keynote	Josef Stefan Conference, Ljubljana, Slovenia
2015	Keynote	Worldwide Innovative Networking (WIN) Conference, Paris, France
	Keynote	International Autophagy Conference, Toulouse, France
	Inaugural IIBB Lecture	Instituto de Investigaciones Biomédicas de Barcelona (IIBB), Barcelona, Spain
	Keynote	French-Japanese Workshop on Big Data in Cancer Research, Paris, France
	Keynote	EMBO Workshop Mac'15 Mitochondria, Apoptosis & Cancer, Frankfurt, Germany
	Keynote	EMBO Conference on Autophagy in Health & Disease, Chia, Italy
	Keynote	International Conference on Resveratrol, Dijon, France
2016	Keynote	2 nd Sino-Euro Experts Conference on Immune Biomarkers, Shanghai, China
	Keynote	ESMO Conference on Immuno-Oncology, Lausanne, Switzerland
	Keynote	6 th Conference on Innovative Therapy, Milan, Italy
	Opening presidential lecture	9 th Internat. Symposium on Neuroprotection and Neurorepair, Leipzig, Germany
	Keynote	Symposium on Cancer Research of the University of Jena, Germany
	IRCM research lecture	Institut de recherches cliniques de Montréal (IRCM), Canada
	Inaugural keynote	Cancer Research Center of the Université Libre de Bruxelles, Belgium
	Leopoldina lecture	International Conference on Innate Immunity, Berlin, Germany
2017	Keynote	Cancer Immunotherapy Symposium, Suzhou Institute, Suzhou, China
	Keynote	Meeting of the Austrian Society for Allergology and Immunity, Innsbruck, Austria
	Keynote	Longevity Conference, Institut Pasteur de Lille, France
	Keynote	1 st Annual Conference USPC-NUS, Singapore
	Keynote	Autophagy & Disease Conference, Sao Paulo, Brazil
	Lecture of the Year	National Cancer Institute, Naples, Italy
	Keynote	Cell Press Conference on Cancer, Inflammation & Immunity, San Diego, CA, USA
Keynote	Breast Cancer Immuno-Oncology Conference, Tampa, FL, USA	
Keynote	Conference of the French Association for Autophagy Research, Paris, France	